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ABSTRACT 
Fluorescence-based assays play key roles in drug discovery and development. 
These assays are widely used due to the widespread availability of fluorescent probes 
and highly sensitive detection platforms. This method is a mainstay of high-throughput 
drug screening (HTS) campaigns, where simple and inexpensive assays are preferred 
for scalability and repeatability. This approach can identify novel chemotypes that may 
lead to new methods to treat disease. To develop a new phenotypic assay for drug 
discovery, we investigated a fluorescent mimic of the anticancer drug Taxol, termed 
Pacific Blue-Gly-taxol (PBGT). This molecular probe binds cellular microtubules and is a 
highly sensitive substrate of the cellular efflux transporter P-glycoprotein (P-gp). When 
HeLa cervical carcinoma cells are cotreated with PBGT (1 μM) and the P-gp inhibitor 
verapamil (25 μM), cellular fluorescence increases by ~ 10-fold as analyzed by confocal 
microscopy or flow cytometry. Because of the simplicity and sensitivity of this assay of P-
gp activity, we envisioned that it could be optimized in a 96-well plate format to provide a 
useful method to investigate cellular efflux mediated by this protein transporter. To 
provide a proof of concept, 1584 diverse compounds obtained from the National Cancer 
Institute (NCI) were screened using automated pipetting and flow cytometry. The primary 
screen yielded more than 23 hit compounds with equivalent or of higher activity than 
verapamil (25 μM). Among these hits, we identified diarylureas that do not appear to 
associate directly with P-gp but rather disrupt the typical rod-like structure of 
mitochondria. These compounds may inhibit P-gp indirectly by affecting mitochondria or 
via a target that additionally affects this organelle. These results demonstrate that PBGT 
is a highly sensitive probe for discovery of inhibitors of P-gp and may allow identification 
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Fluorescent Probes in Drug Discovery 
Despite recent advances in medical science, humans continue to suffer from a wide 
variety of diseases. Although treatments for many diseases have drastically improved in 
the past century, a large unmet medical need remains for incurable or otherwise ongoing 
chronic conditions. In 2019, the US Center for Disease Control estimated that 6 out of 10 
adults suffer from a chronic illness, and treatment of these illnesses is a leading driver of 
the 3.3 trillion dollars needed annually for healthcare in the USA.1 In addition, patient non-
adherence, which is often due to undesirable side effects of prescription medication, has 
been linked to negative healthcare outcomes, higher rates of hospitalization, and 
increased overall healthcare costs.2-3  
To bridge this gap between patients who suffer from treatment-resistant diseases and 
therapies with more positive outcomes, pharmaceutical companies have invested 
copious amounts of time and money on drug discovery. In recent years, many innovative 
new medicines stem from advances in the field of chemical biology, a research area 
focused on using methods of chemistry to interrogate biological function. Often, studies 
in chemical biology lead to an enhanced understanding of the underlying mechanisms of 
disease and push the boundaries of how scientists can manipulate native biological 
function. These efforts have afforded new biological targets for drugs, new methods to 





1.1. Fluorescence-based assay development 
Numerous methods have been developed for interrogating the function of 
biomolecules. In the field of chemical biology, fluorescence-based approaches are 
particularly widely used because of the high sensitivity of this method, its ease of use, 
and the diversity of available fluorescent probes.7 Fluorescent probes can be designed to 
localize in specific tissues, cells, or subcellular regions of biological samples or whole 
organisms. This localization can be an important tool for bioimaging applications.8 In 
addition, because intracellular compartments and organelles can maintain specific 
signaling molecules, metabolites, and ions, some fluorescent probes can be used as 
biosensors that react with endogenous or exogenous molecules to create or release a 
fluorescent molecule that can be detected. Biosensors that localize to specific organelles 
can be particularly useful for understanding the subcellular dynamics and abundance of 
analytes.9 Although other important applications of fluorescent probes can be found 
outside of chemical biology, this thesis is primarily focused on studies of specific types of 
bioimaging agents and biosensors.  
 
1.1.1 Introduction to fluorescence spectroscopy 
Since its first observation by Fredrick Herschel in 1845, and its subsequent 
rationalization in 1852 by G.G. Stokes, the photophysical property of fluorescence has 
provided an important tool to qualitatively and quantitatively analyze a wide variety of 
biological phenomena.10-12 Fluorescence, a distinct form of photoluminescence, is the 
emission of light from a substance that has absorbed light or electromagnetic radiation at 
a shorter wavelength.13 This process is governed by three main steps as detailed in 
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Figure 1.1. The first step in the process, excitation, occurs when a photon from a source 
of light or electromagnetic radiation is absorbed by a fluorescent compound or material 
termed a fluorophore. This causes electrons of the fluorophore to transition from the 
ground state (S0) to an excited state. Next, the fluorophore undergoes vibrational 
relaxation, where the fluorophore relaxes to the lowest energy level of the excited state 
(S1). Last, the fluorophore emits a red-shifted photon as it returns its ground state (S0) by 
the process of emission.14   
 
FIGURE 1.1. A Jablonski diagram illustrating the three-step process of fluorescence. A 
photon is absorbed by a fluorophore that subsequently emits a photon of a longer 
wavelength. 
 
Fluorophores can be characterized by their excitation and emission spectra. The 
wavelengths of the maximum peaks in these spectra are denoted as the excitation and 
emission maxima. The difference between these wavelengths is termed the Stokes 
shift.15 When choosing a fluorophore for a fluorescence-based assay, it is important to 




















excitation and emission maxima (small Stokes shift), the sensitivity of fluorescence-based 
assays can be limited because of the difficulty in separating the light used to excite the 
fluorophore from its fluorescence emission.16  
In bioassays involving more than one fluorophore, fluorophores generally need to be 
spectrally orthogonal, ideally with emission and excitation bands that are non-overlapping 
and relatively narrow. However, in some instances it is desired for the emission of one 
fluorophore to overlap with the excitation band of another fluorophore. If the fluorophores 
are in sufficiently close proximity, this can produce a donor-acceptor interaction between 
the emission of the shorter wavelength fluorophore and the excitation of the longer 
wavelength fluorophore. This phenomenon is the basis of Förster Resonance Energy 
(FRET) and has been extensively used to interrogate biological processes.17-20 However, 
in this thesis, the experiments described will focus on simpler measurements of biological 
activity that rely on fluorescence intensity. 
 
1.1.2 Common fluorescent small molecules 
 Many compounds, both natural and synthetic, are intrinsically fluorescent.21-22 
Most fluorescent small molecules contain multiple conjugated pi bonds and are frequently 
polycyclic aromatic compounds. These highly extended conjugated systems can greatly 
decrease the energy difference between the S0 and S1 states of the fluorophore. In turn, 
this decreases the energy of light needed to excite the fluorophore, meaning that a longer 
wavelength of light can be used for excitation. Examples of some small molecule 
fluorophores organized relative to their absorption and excitation maxima (Omax) are 
shown in Figure 1.2.  
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Figure 1.2. Examples of fluorescent small molecules organized by excitation wavelength. 
From left to right, the fluorophores tryptophan, Pacific Blue, Fluorescein, BODIPY, and 
Cy5 are shown. The core structures of fluorescein, BODIPY, and Cy5 have been 
extensively modified to further tune spectral properties and generate numerous other 
fluorophores for fluorescence-based assay development. 
 
 Although molecular structure plays a large role in the spectroscopic properties of 
small molecules, other factors can influence absorption/excitation and emission spectra. 
For some fluorophores, environmental factors such as pH, solvent, and the molecular 
environment, such as whether or not the fluorophore is bound to a specific protein, have 
profound effects on fluorescence properties.23 Consequently, when new fluorophores are 
designed or discovered, their spectral properties are generally assessed in a variety of 
different conditions such as varying pH in aqueous buffers and in different solvents.24-27  
Additionally, because the spectral properties of a fluorophore can change in a 
protein-bound vs unbound state, assays have been developed to detect these differences. 
One of the most common protein binding assays relies on fluorescence polarization, 























which measures the fluorescence of a fluorophore upon excitation with plane-polarized 
light. In this assay, a small fluorophore that is unbound would theoretically be in rapid 
motion and upon excitation with plane polarized light will emit light in multiple different 
directions compared with the excitation plane. However, a fluorophore bound to a much 
larger molecule such as a target protein, would have less free motion, causing the 
emission of polarized light. This increase in fluorescence polarization provides a method 
to measure the affinity of small molecules to proteins through direct interactions or 
competition assays. This method has played a critical role in protein biochemistry and 
has been extensively used multiple subfields such as immunoassays. 28-29 In addition, 
fluorescence polarization is frequently used in high-throughput screening to find small 
molecule binders for a variety of different proteins. 30-33  
 
1.1.3 Fluorescent proteins 
 Another method used to develop fluorescence-based assays involves intrinsically 
fluorescent proteins and related fluorescent fusion proteins. Fusion proteins are designer 
protein products that can be prepared by recombinant DNA technology. This molecular 
biology approach can combine DNA fragments from different species, reinsert the 
recombinant DNA back into a host organism, and express proteins of interest fused to 
intrinsically fluorescent proteins for analysis.34 Fluorescent proteins are often used for 
studies of subcellular localization of other fused proteins and to confirm gene expression 
by generation of fluorescent cells.37 Fusion proteins have also been crucial for the 
development of multiple biologic drugs including Fc-fusion proteins.35-36  
 7 
Green fluorescent protein (GFP) is one of the most widely investigated intrinsically 
fluorescent proteins. Initially isolated from Aequorea Victoria in 1962 by Shimomura et 
al.,38 more than three decades passed before GFP was widely employed by scientists 
outside of the marine biology community.39 In 1994, it was first reported that GFP could 
be used as a marker for gene expression experiments.40 These findings became 
recognized as a major scientific breakthrough, and fluorescent proteins have since been 
widely utilized as tools for studies of cellular and developmental biology. Much time and 
effort has been spent in both improving and expanding the palette of fluorescent 
proteins.41 This work has led to the creation of dozens of fluorescent proteins with distinct 
spectral properties that can be used to develop fluorescence-based biological assays.  
 
1.2 Qualitative and quantitative analysis of cellular fluorescence 
 Sensitive and reliable methods have been developed to use fluorescence to 
analyze cellular properties and intracellular dynamics. Qualitative methods can readily 
detect cellular events and the subcellular localization of fluorophores in real time. In 
addition, quantitative methods can be used to measure the abundance and dynamics of 
endogenous and exogenous biomolecules. Whereas there are many ways to analyze 
these properties, flow cytometry and fluorescence microscopy are two of the most widely 
used methods for qualitative and quantitative evaluation of cellular fluorescence.42-44 
 
1.2.1 Flow cytometry 
 Flow cytometry is a powerful tool for high-content fluorescence-based analysis of 
cells and other suspended particles. A flow cytometer can measure multiple physical 
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properties by flowing suspended cells past a monochromatic light source (generally a 
laser). In turn, light is emitted from individual cells and collected via a series of emission 
filters.45 The scattering of this light can be related to the size and shape of the cell. The 
intensity of light that is emitted from cells and isolated by the filters is reported in arbitrary 
fluorescence units. A diagram of this process is shown in Figure 1.3. 
 
Figure 1.3. Principles of flow cytometry. A sample of cells in suspension is injected into 
the instrument. The concentrated cells are diluted with sheath fluid and subsequently flow 
single-file past a light source. The scattering of this light and the emission of longer 
wavelength light by the cell can be assessed by the instrument. 
 
Flow cytometry is used in multiple subfields in biology. In particular, this method 
has played an important role in clinical microbiology and oncology where it is used to 
detect various microbial infections and cancers.46-49 Additionally, because this process is 
relatively fast and allows for a multiparametric analysis of each cell, it has also become 














campaigns.50 For example, high-throughput flow cytometry has become a core discovery 
technology within the major pharmaceutical company AstraZeneca.51  
 Even though flow cytometry is a fantastic tool to quantify cellular fluorescence, 
there are also disadvantages to this method. An increase in fluorescence intensity 
obtained from this method will only indicate that the cell is becoming brighter, not precisely 
why the sample is increasing in brightness. In drug screens, cellular fluorescence and 
morphology can provide a reasonable phenotype to assay against, but additional studies 
of subcellular localization are often needed to provide important information about the 
mechanism of changes in fluorescence. 
 
1.2.2 Confocal laser scanning microscopy 
 Another high-content fluorescence-based method relies on confocal laser-
scanning microscopy and related confocal microscopy techniques. This imaging method 
can be used to investigate biological processes within living cells and the impact of 
xenobiotics on cellular fluorescence. Other types of fluorescence microscopes are often 
used for imaging, but confocal microscopes can uniquely acquire thin (micron-thick) 
optical slices to create high resolution images.52 This process removes out of focus light 
that reduces the clarity of fluorescent images generated with traditional wide-field 
microscopes. Whereas wide-field (e.g. epifluorescence) microscopes are often more 
sensitive than confocal microscopes, the thin optical slices of a confocal microscope can 
be used to create 3D reconstructions of samples and are generally better suited for 
quantitative microscopy applications.53 
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 Due to the high resolution of confocal images, this method is widely used to 
investigate the cellular mechanism of action of small molecules. Cellular organelles, 
proteins, and nucleic acids can be labeled with fluorescent dyes and imaged in high 
definition using confocal microscopy.54-56 Fluorescent analogues of compounds can be 
synthesized and tested to observe their subcellular localization, suggesting potential 
mechanisms of action.57-58 Studies of the subcellular localization of fluorescent fusion 
proteins can also provide useful mechanistic information. Furthermore, biomolecular 
interactions in cells can also be assessed by co-localization or FRET-based assays using 
orthogonally fluorescent fusion proteins, two orthogonally fluorescent small molecules, or 
both a fluorescent fusion protein and an orthogonally fluorescent small molecule.59-60  
 
1.3. High-throughput and high-content screening methods 
An important application of fluorescence-based assays for drug discovery involves 
high-throughput screening (HTS). HTS employs large chemical libraries for rapid 
screening against biological targets of interest to identify chemical modulators.61 
Compounds found to be the most active are termed “hits” and are moved forward in the 
discovery process. Their activity can then be improved in a hit-to-lead campaign. During 
preclinical drug development, the pharmacokinetic/pharmacodynamic properties of the 
best lead compounds are optimized before compounds are advanced to clinical trials.62 
However, in the past two decades, the difficulty in identifying high-quality hits via HTS has 
been suggested to be a contributor to the slowing productivity of the pharmaceutical 
industry.63-64 However, a paper from Macarron et al, published in Nature Reviews Drug 
Discovery in 2011, aimed to dismiss these accusations and illustrate the benefits of HTS 
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for drug discovery.65 Although not all screens directly put a compound on the market, HTS 
campaigns have proven successful in other areas such as providing chemical probes that 
can later be used in basic research to influence drug discovery in different ways.66 In 
addition, these screens have been particularly successful at identifying novel chemotypes 
active against particular biological targets.67-69 
Fluorescence-based HTS approaches have been widely used due to the potential for 
high sensitivity and versatility. For HTS campaigns, fluorescence intensity, fluorescence 
polarization, FRET, and fluorescence correlation spectroscopy (FCS) assays have been 
widely used,70 Compared to fluorescence intensity, FCS is a more complex technique 
that relies on analysis of fluctuations in fluorescence intensity over time. In a closed 
system, Brownian motion of fluorescent molecules causes fluctuations in the fluorescence 
intensity. Events such as chemical reactions or other biomolecular interactions can 
disrupt these baseline fluctuations and can be detected by a device such as a high 
resolution confocal microscope.71-72 FCS experiments generally interrogate mesoscopic 
systems and only require concentrations of fluorescent molecules in the nanomolar 
range.73 Due to the high costs of a large HTS campaign, a method which requires such 
small amounts of material such as FCS would be ideal. However, FCS has its limitations. 
Although effective in vitro, limitations associated with studies of living cells have hindered 
use in drug discovery, but recent efforts have been directed at further development of this 
method for this application.74-75 
HTS assays that rely on measurements of fluorescence intensity on multiwell plates 
are common due to their simplicity.76 Modern plate readers can analyze absorbance and 
fluorescence using a variety of different plate formats, typically using 96, 384, or 1526 
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wells/plate. Additionally, because the screening process can be completed for an entire 
assay plate in minutes or less, this sample format is generally desirable for large HTS 
campaigns where hundreds of thousands of compounds are assayed. A plate reader 
works by shining a light source, either from a lamp, laser, or light emitting diode, on each 
individual assay well. Filters or monochrometers can collect light emitted corresponding 
by the fluorophore used in the assay.77 However, plate reading can generate false positive 
data resulting from intrinsically fluorescent library compounds.  
 Even though false positives are present in most screens, there are methods which 
can lower their occurrence and make their detection simpler. An exemplary method is 
that of high-content screening (HCS), which obtains detailed information regarding cell 
morphology and multi-color fluorescence in each individual assay. Each assay 
investigates more than one parameter and not a single read-out like a plate reader, so 
false positives and false negatives can be more easily ruled out.78 HCS was first reported 
in 1996 as a method to ease downstream bottlenecks in the drug discovery process such 
as target validation and lead optimization.79 Since the initial discovery of HCS, there have 
been many advances in data mining of cellular populations,80 automated microscopy,81 
and systems biology.82 These advances have allowed HCS to become a widely used tool 
for phenotypic drug discovery.83  
Although HCS has been widely successful, this method is not without its limitations. 
As an increasing number of parameters are used to analyze cells and screening libraries 
become larger, the data generated from each screen increases substantially. To counter 
this complexity, much effort has recently been focused on the incorporation of deep 
learning techniques within HCS.84-85 One such technology, intelligent image-activated cell 
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sorting, has been developed by Nitta et al in 2018.86 In this method, a technology was 
developed to autonomously sort microalgal and blood cells by subcellular protein 
localization and cell-cell interactions. Whereas this technology was piloted using only two 
cell types, it is expected to be translative to other cell types and perhaps larger cell 
spheroids, tissues, and small organisms. Moreover, this technology serves as a prime 
example of the incorporation machine learning in HCS. Such discoveries reduce the need 
for human-mediated data mining, and could be particularly useful in the development of 
large HCS screens where vast amounts of data are generated.  
HSC has also been incorporated into other scientific disciplines such as translational 
and precision medicine.87 For traditional biomedical applications, HCS analyzes cell 
phenotypes in the presence of libraries of small molecules. In contrast, HCS for precision 
medicine utilizes patient-derived cell lines and small molecules as possible therapeutics. 
This approach could lead to a deeper understanding of the sensitivity profile of a particular 
cell line and lead to better patient outcomes. An example of this strategy was recently 
published by Yu et al.88 In this study, 83 FDA approved chemotherapeutics were screened 
against seven cell lines derived from patients with glioblastoma (cultured as both 
monolayers and 3D neutrospheres). This method identified several non-standard 
chemotherapeutics that were efficacious in vitro against primary and recurrent 
glioblastomas. This assay could be useful in identifying new therapies to treat patient-
specific cancers. 
In a different study conducted by Prins et al, a high-content assay was developed for 
precision medicine discovery in cystic fibrosis (CF).89 CF involves mutations in a gene 
that encodes a particular ion channel, the cystic fibrosis transmembrane conductance 
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regulator (CFTR). This new high-content assay focused on assessing CFTR’s function 
and the membrane density of its variants by utilizing multicolored halide-activated CFTR 
proteins. As a proof of concept, the known CFTR potentiator VX-770 was screened 
against 62 CFTR variants. Data from this screen showed that this compound was not 
efficacious in CFTR variants bearing mutations at a particular ATP-binding site. Moreover, 
this high-content assay could be useful to screen compounds against patient specific 
CFTR mutations. Both of these two examples illustrate that HCS could also be an 
important tool in the development of precision medicines of the future.  
 One platform often utilized for HCS is high-content flow cytometry. This method 
allows for a large population of cells within an assay well to be analyzed. Since flow 
cytometry is a high-content technique, much more information can be obtained per assay 
well than possible with a traditional plate reader. For example, since the morphology of 
each cell is evaluated by light scattering, cytotoxicity of library compounds can be 
assessed in the primary screen.90 This approach saves time and money by avoiding some 
of the need for downstream cytotoxicity assays on hit compounds. Flow cytometry can 
readily detect the accumulation of a fluorescent compound or the production of a 
fluorescent protein within cells.91-93 These types of high-content assays could be 
potentially useful for studies of drug resistance related to cellular efflux. We describe in 
Chapter 2 a fluorescent efflux substrate that can be used in a phenotypic screen to 
discover novel chemotypes that inhibit cellular efflux of small molecules involving the 




1.4  Conclusions 
Fluorescence-based assays have played a crucial role in the understanding of 
biological processes and in the development of new medicines. Due to their sensitivity, 
ease of use, and diversity of possible probes, they have been a mainstay for chemical 
biologists who seek to investigate and manipulate biological function. To keep up with the 
needs of biomedical scientists, the toolbox of fluorescent probes and palette of 
fluorescent proteins has been consistently expanding. In addition, methods which these 
tools can be analyzed are becoming increasingly sensitive and optimized for high 
throughput and high-content screening. The continued development of these types of 
probes and methodologies will allow for a deeper investigation into a wide variety of 
biological processes. These findings contribute to our understanding of the etiology of 
human disease and provide new approaches for the discovery and development of 
therapeutics.  
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Discovery of novel small molecule inhibitors of efflux involving P-glycoprotein 
Cancer is a collection of related diseases. Whereas cancers can start almost 
anywhere in the human body, their etiology results from dysregulated cell growth.1 For 
some cancers, these unregulated cells grow into a mass called a tumor, and malignant 
cancers can metastasize to a variety of different locations in the body. Eventually, normal 
biological function can be disrupted, decreasing the overall quality of life of the patient, 
and potentially leading to death. Cancer therapies have drastically improved in the past 
century and there are now many options for treatment including small molecule 
chemotherapeutics, radiation, immunotherapy, and surgery.2-4 Common classes of small 
molecule chemotherapeutics include DNA alkylating agents,5 antifolates,6 DNA 
intercalators,7 tyrosine kinase inhibitors,8 and tubulin binding agents.9 Although the 
mechanisms of which these treatments vary, they result in antiproliferative effects on 
cancer cells.  
While existing therapies have been successful in treating some types of cancer, drug 
resistance remains a major limitation to the effectiveness to small molecule 
chemotherapeutics.10 Although this resistance can result from multiple potential 
mechanisms, the overexpression of multidrug efflux pumps such as P-glycoprotein (P-gp) 
often plays a key role. Consequently, cancers that highly express P-gp have been linked 
to poor prognoses for patients.11 This ATP-dependent efflux pump decreases the 
intracellular concentrations of xenobiotics by cycling between outward and inward facing 
conformations that traverse the cell membrane. Recently, a cryo-EM structure of the 
human P-gp in its outward facing conformation was reported12 and compared with a 
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structure of the inward facing conformation of mouse P-gp, providing key insight into its 
mechanism of cellular efflux (Figure 2.1).12 
In addition to its role in cancer biology, P-gp is a target of interest to increase the 
uptake of compounds with poor bioavailability, due to its expression in enterocytes that 
line the intestine.13 Although much effort has been made to inhibit or reduce the 
expression of this protein using small molecules, there are currently no FDA approved 
drugs that specifically target this protein. Compounds that have entered clinical trials to 
evaluate efficacy in inhibiting P-gp have often failed due to lack of potency or toxicity due 
to the presence of P-gp in healthy tissues such as at the blood brain barier.14 The 
development of novel probes of pathways that influence P-gp activity could shed light on 
potential new approaches for inhibition of drug resistance. Furthermore, using these 
probes to find new inhibitors in high throughput screening campaigns could lead to the 
discovery of novel chemotypes or mechanisms that inhibit this major drug transporter.  













Figure 2.1. Comparison of structures of inward-facing mouse P-gp (left) and outward-
facing human P-gp (right) as described by Kim et al.12 When bound to two ATP molecules, 
the two nucleotide binding domains (NBDs) dimerize and reorient the drug binding 
domain into the intracellular space. These structures indicate that ATP binding, rather 





Whereas P-gp can transport a broad spectrum of diverse substrates, a notable 
substrate in the context of cancer biology is the widely used chemotherapeutic drug 
paclitaxel (Taxol).15 The Peterson group previously developed novel fluorescent 
analogues of Taxol that contain the coumarin-derived drug-like fluorophore Pacific Blue.16 
Unlike other widely used fluorescent taxoids, such as commercially available Flutax-2, 
one of these analogues, Pacific Blue-Gly-Taxol (PBGT, structure shown in Figure 2.2a), 
was found to maintain substantial cytotoxicity. Additionally, similar to Taxol, PBGT readily 
binds microtubules in living cancer cells. However, this probe is a highly efficient substrate 
of P-gp, and inhibition of P-gp by cotreatment with the small molecule verapamil is 
necessary to observe high levels of fluorescence in most living cell lines. When HeLa 
cervical carcinoma cells are cotreated with PBGT (1 PM) and verapamil (25 PM), cellular 
fluorescence increases by ~ 10-fold as analyzed by flow cytometry or confocal 
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Figure 2.2. (A) The structure of Pacific Blue-Gly-Taxol (PBGT). (B) Previously reported15 
flow cytometry data showing the fluorescence of unstained HeLa cells, HeLa cells dosed 
with PBGT (1 PM, grey histograms), and HeLa cells additionally co-treated with verapamil 
(25 and 100 PM). C) Previously reported16 confocal laser scanning microscopy images of 
HeLa cells treated with PBGT (1 PM). Cells in the left panel were treated with PBGT alone 
and cells in the right panel were co-dosed with verapamil (25 PM). Cells were excited at 
405 nm and the fluorescence emission was collected from 425-500 nm.16 Scalebar = 10 
microns. 
 
Because of the simplicity and sensitivity of this assay, we envisioned that it could 
provide a useful method to investigate cellular efflux mediated by P-gp. Small molecules 
that inhibit P-gp would theoretically cause P-gp expressing cells to accumulate a higher 
amount of PBGT and increase cellular fluorescence. High-content flow cytometry could 
also be used to screen against this phenotype while also providing a multi-parameter 



















What makes PBGT such a useful probe of P-gp is its ability to detect accumulation in 
cells that express low levels of P-gp. Other probes, such as rhodamine 123 and calcein-
AM, have been used to screen for novel inhibitors of P-gp.17-19 However, the Peterson 
laboratory has previously shown that in HeLa cells PBGT is much more sensitive than 
rhodamine 123 as a probe of P-gp.16 To further explore its sensitivity, we recently 
compared this compound with Calcein-AM. This P-gp substrate is a pro-fluorophore ester 
derived from the green fluorescent fluorophore calcein (Figure 2.3a). It accumulates in 
cells and its esters are cleaved by esterases. This releases the fluorescent derivative 
calcein, which is highly charged and can no longer traverse the plasma membrane. In 
cells that express high levels of P-gp, this process is hindered due to efflux of the cell-
permeable pro-fluorophore. Similar to PBGT, inhibition of P-gp increases cellular 
fluorescence due to the accumulation of calcein-AM and its product fluorophore calcein. 
To compare these two probes, cells were dosed with calcein-AM (0.25 PM), PBGT (1 PM), 
and co-dosed with verapamil (25 PM and 100 PM) in Jurkat lymphocytes.  The cells were 
incubated for 1 h at 37 °C and analyzed via flow cytometry. This treatment with PBGT 
resulted in a 6.2-fold increase in fluorescence between wells in the absence and presence 
of verapamil (25 PM). In contrast, calcein-AM showed a smaller 1.4-fold increase in 
fluorescence. In addition, PBGT could detect changes in inhibitor concentrations with 
greater sensitivity. For calcein-AM, a significant (p = 0.018)  difference was observed in 
the fluorescence of cells treated with verapamil at 100 µM and 25 PM, however PBGT 
measured a more significant (p = 0.0014) 1.7-fold increase in fluorescence when the 
verapamil concentration was increased from 25 µM to 100 µM. This data provides 
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evidence that PBGT is a much more sensitive probe than Calcein-AM for detection of P-
gp in Jurkat lymphocytes (Figure 2.3b). 
A)           
B)    
Figure 2.3. (A) Structure of the profluorophore Calcein-AM and the product 
fluorophore calcein resulting from hydrolysis by esterases. (B) Fluorescence of Jurkat 
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2.2 Considerations for primary screening by flow cytometry 
 Because it is such a sensitive probe, we envisioned that PBGT could be used in a 
phenotypic screening campaign to discover novel inhibitors of P-gp mediated efflux. In 
particular, we investigated high-content flow cytometry as a screening platform. This 
approach would allow multiparametric analysis of compound activity including both 
cellular fluorescence and acute cytotoxicity. To turn this idea into a feasible screen, we 
still needed to choose a suitable small molecule library, optimize the original assay for 
96-well plates, and plan a counter-screen to eliminate the intrinsic fluorescence of some 
library members. Section 2.2 will focus on methods used to develop a P-gp assay suitable 
for screening of living cells by flow cytometry on 96-well plates. 
 
2.2.1 Selection of a chemical library 
 On the surface, high throughput screening can be compared to a game of darts 
that is played in the dark, where random compounds are screened against a target of 
interest in hopes of finding some “on-target” hits. In reality, careful selection of an 
appropriate small molecule library is critical for a successful screen. In terms of how these 
small molecule libraries are assembled, they generally exclude compounds with reactive 
moieties that cause systemic toxicity and Pan-assay interference compounds (PAINs) 
that can lead to false positives.20-21 Libraries generally include diverse small molecules of 
varying complexity. More recently, focused libraries have been developed to target 
specific proteins.22 These libraries contain families of small molecules that are generally 
known to be active modulators of a particular protein or protein type such as G-protein 
coupled receptors, kinases, and voltage-gated ion channels. Selection of a library 
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generally takes into account the target of interest and the physiochemical properties 
required in a drug candidate. For instance, if a screen was developed to discover a small 
molecule modulator of a central nervous system target, screening compounds with poor 
blood brain barrier penetration would be counterproductive towards the end goal.  
 The library we chose for this screen was the NCI diversity set VI library. This library 
is a made up of 1584 diverse small molecules and is derived from a 140000-compound 
repository. The 1584 compounds in this library are made up of a number of diverse and 
relatively rigid small molecules and is available arrayed on twenty 96-well plates. 
Pharmacological liabilities such as electrophiles, polycyclic aromatics, and 
organometallics have been excluded from this library.23 Besides its diverse range of 
compounds, it also contains some known P-gp substrates. While this feature would not 
aid us in finding novel inhibitors of P-gp, detecting these molecules in our screen could 
further validate that this phenotypic screening method might identify inhibitors of this 
major efflux protein.  
 
2.2.2 Choosing a suitable non-adherent cell line 
 Due to the sheer size of a screening campaign, it is critical to remove or replace 
non-essential assay steps that are repetitive or error prone. One such non-essential step 
in the initial cellular studies of PBGT was the trypsinization of adherent HeLa cells 
required for analysis by flow cytometry. Because we intended to use flow cytometry as a 
detection platform, the cells need to be in suspension prior to analysis. To simplify the 
assay, we reasoned that the use of a non-adherent cell line could allow us to forgo this 
additional step. 
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 To find a non-adherent cell line suitable for detection of P-gp activity, we added 
PBGT (1 PM) alone and coadministered with the P-gp inhibitor verapamil (25 PM and 100 
PM) to the suspension cell lines Ramos, Raji, HL-60, and Jurkat and compared these 
results with trypsinized HeLa cells. Although Jurkat cells did not exhibit the highest 
fluorescence intensity, this cell line had the highest fold increase when treated with PBGT 
(1 PM) compared with a combination of PBGT (1 PM) and verapamil (25 PM). These 
results indicated that the Jurkat cell line would allow us to readily detect changes in 
accumulation of PBGT and was selected for the screen.  
 
 
Figure 2.4. Fold increase in different cell lines. Trypsinized HeLa, and the suspension 
cell lines Ramos, Raji, HL-60, and Jurkat cell lines were treated with PBGT (1 PM) alone 
and in conjunction with verapamil (25 and 100 PM), incubated for 1 h at 37 °C, and 




































2.2.3 Assay automation 
 To further improve the screening process, we employed an automated Integra 
pipetting robot. This robot uses a multichannel pipette attached to a robotic arm to allow 
transfers between different 96 or 384 well plates. We utilized this robot in both the seeding 
of Jurkat cells and for treatment with library compounds. Because the media of the cells 
was supplemented with concentrated PBGT prior to seeding in a 96 well plate, the 
concentration of the probe should be consistent throughout all 96 wells of each plate. 
Library compounds were transferred using this robot to allow accurate delivery to each 
well. 
 
2.2.4 Assessment of intrinsic fluorescence 
 A potential complication associated with this screening approach was the 
possibility that particular library members might be intrinsically fluorescent and detected 
with the same emission filter as our probe. To assess this issue, each 96 well plate was 
treated with library compounds and analyzed via flow cytometry before running the assay 
plate with PBGT. This allowed subtraction of intrinsic fluorescence from assay 
fluorescence values to give a more accurate measurement of the fluorescence changes 
due to cellular uptake of PBGT. 
 
2.2.5 Controls 
 The last consideration was the positive and negative controls to include on each 
assay plate. Negative controls consisted of three wells treated with only the DMSO 
vehicle. These controls are vital because they exemplify data from what should be a 
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healthy population of cells. The light scattering histogram of these cells can be gated in 
the flow cytometry software and compared to each assay well to assess any rapid 
cytotoxic effects. Positive controls consisted of at least three wells for each of two different 
concentrations of verapamil (25 PM, 100 PM). These wells on each plate were critical for 
the accurate analysis of all of the library compounds. Cell-based assays are sensitive, 
and variations can be observed with very slight changes in assay conditions including cell 
passage number and density (or confluency).24-25 Having these controls provided a 
means to compare the effects of library inhibitors in comparison to the known competitive 
inhibitor verapamil. If the final analysis used only a single fluorescence measurement, 
these values would be a less accurate assessment of compound activity. 
 
2.3 Analysis of data from screening the NCI Diversity Set-VI library 
 After the assay was optimized, all 1584 compounds in the NCI diversity set VI were 
screened and analyzed. We aimed to analyze the data in such a way that each plate can 
be compared to one another with minimization of false positives. The intrinsic 
fluorescence intensity of the library compound, evaluated on the same day and same cell 
passage number, was subtracted from the assay fluorescence intensity. This adjusted 
fluorescence intensity was then divided by the fluorescence intensity of PBGT (1 PM) to 
yield the fold increase in fluorescence intensity due to the library compound. This fold 
increase value was then divided by the fold increase for 25 PM verapamil to give the 
percent activity compared with 25 PM verapamil. Finally, to account for any rapid cytotoxic 
effects of the library compound, we multiplied by the percent viability. Rapid cytotoxic 
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effects resulted in enhanced cellular fluorescence and including this factor reduced the 
frequency of false positives. This equation is shown in Figure 2.5. 
 
Figure 2.5. HTS analysis equation: The above equation was used to analyze 
fluorescence intensities from the screen. Variables: FA = assay fluorescence, FI = 
intrinsic fluorescence, NC = mean of negative control (1 PM PBGT wells), PC = fold 
increase of positive control (25 PM verapamil wells). 
 
After each value for fluorescence intensity was converted into percent activity of 
25 µM verapamil, we plotted this data as a histogram for further comparison. This 
histogram is shown in Figure 2.6. Each plate is represented by a different symbol and on 
the X-axis is each well of the 96 plate. On the Y-axis is the percent activity of 25 PM 
verapamil with the cytotoxicity factor included.  
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Figure 2.6. Histogram of treated screening data: Primary median fluorescence after 
screening of the NCI diversity set VI against PBGT in Jurkat lymphocytes. Compound 
activity is shown based on each well of a 96-well assay plate. Each plate is represented 
by a different symbol as shown in the key. For each “hit compound”, defined as greater 
than the median + 3 SD, the corresponding NSC number is provided. 
 
 The cutoff we chose for “hit” compounds was 3 times the standard deviation of all 
of the library values plus the median of all of the library values. This cutoff is shown as a 
dotted line in Figure 2.6. This analysis ensures that our hits are far enough away from the 
median value and are significantly different than the average library member. This method 
of analysis provided 23 hit compounds and a hit rate of 1.45%. While most high-
throughput screens generally have a hit rate of less than 1%,26 it is understandable that 
a screen focusing on efflux related to the notoriously promiscuous P-gp might have a 
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higher than normal hit rate.27 A sorted list of these hits based on their % activity of 25 
verapamil is shown in Figure 2.7. 
 
Figure 2.7. Ranked hits: Hit compounds of 3 times the standard deviation of the median 
library values or greater are shown above. They are ranked based on percent activity 
compared with 25 PM verapamil. 
 
 
2.3.1 Families of small molecule hits 
 Within the 23 hit compounds which came out of this screen, there were several 
distinct families that displayed high structural similarity to each other. The first family of 
inhibitors we will outline are the phenothiazines and associated compounds. A complete 
list of hit molecules containing either a phenothiazine or the ring expanded NSC 281816 























































































Figure 2.8. Phenothiazines and associated compounds: Structures and NSC 
numbers of phenothiazine hits and the related compound NSC 281816. 
 
 Phenothiazines have been studied for a wide variety of biomedical applications 
and are considered to be a privileged scaffold in medicinal chemistry.28 The discovery of 
this scaffold is not a novel finding because this class of compound has already been well 
studied for their role in the modulation of multidrug resistence.29-30 In particular, they have 
been shown to be antagonists of P-gp mediated efflux and conversely they have been 
linked to stimulation of multidrug resistance-associated protein 1 (MRP1).31 While this 
class of compounds was already known to inhibit P-gp, the fact that such compounds 
were detected up by our screen further validates that our assay can detect modulators of 
P-gp mediated efflux. 
 The next class of hits found to inhibit cellular efflux of PBGT was a family of 
carbazole-containing compounds. Carbazoles are structurally analogous to the 
previously discussed phenothiazines, and they can be synthesized from them via a ring 
contraction to extrude the sulfur atom of the phenothiazine.32 Carbazole and associated 















NSC 281816 NSC 24113 NSC 18883 NSC 303612
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Figure 2.9. Carbazole and associated hits: Structures and NSC numbers of carbazole 
hits and the related compound NSC 638432. 
 
 Since carbazoles have a high structural similarity to the previously discussed 
phenothiazines, it is reasonable to envision that they could also be inhibitors of P-gp 
mediated efflux. These compounds have not been extensively studied as modulators of 
cellular efflux, but some carbazole-containing compounds have been shown to be 
substrates of P-gp.33 Similarly, some compounds with in vitro efficacy against Alzheimer’s 
targets have shown decreased in vivo efficacy due to P-gp mediated efflux at the blood 
brain barrier.34-35 These findings support that P-gp modulation is detected by our assay, 
however these compounds were not pursued further due to their lack of novelty. 
 A major class of compounds identified from the primary screen were diaryl 
derivatives. These simple compounds generally link two aryl groups together by either a 
urea, carbamate, or amide bond and is the largest family of compounds identified from 
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Figure 2.10. Diaryl and associated compounds. Structures and NSC numbers of diaryl 
ureas, carbamates, and amide-containing hit compounds. 
 
 Although these diaryl compounds are relatively simple organic molecules, they 
have not been previously reported as inhibitors of P-gp-mediated cellular efflux. 
Furthermore, these diaryl compounds are not known to be substrates for efflux by P-gp. 
Consequently, we hypothesized that these agents might provide a new chemotype for 
inhibition of cellular efflux involving P-gp. 
 
2.4 Diarylureas as novel inhibitors of cellular efflux 
 Due to their novelty as cellular efflux modulators, and unexplored mechanism of 
inhibition, we further investigated the activity of the diarylureas. In the past, urea has been 
extensively studied for its role as a destabilizing agent that can disrupt critical hydrogen 
bonds of proteins.36-37 Furthermore, diarylureas have become a privileged structure in 
anticancer agents and exhibit a wide range of antiproliferative activity in cells.38-40 











































were conducted using flow cytometry. Further experiments to investigate possible 
mechanisms of inhibition were conducted using confocal laser scanning microscopy. 
 
2.4.1 Hit validation 
 To confirm the activity and to assess the relative potency of these compounds, as 
shown in Figure 2.11, we generated a dose response curve with our most active 
diarylurea hit, NSC 202705. The dose response curve was generated in comparison with 
verapamil with Jurkat lymphocytes, 1 PM PBGT, and the urea from 100 PM to 100 pM in 
1:10 dilutions. 
 
Figure 2.11. Dose response data NSC 202705 in the PBGT/Jurkat efflux assay. Cells 
were treated with inhibitors at concentrations ranging from 100 PM to 100 pM, incubated 
for 1 hour at 37 °C, and analyzed by flow cytometry.   
 
 From this dose-dependent inhibition data, NSC 202705 initially appeared to be 
more potent with potentially higher efficacy than verapamil. Based on the best curve fit 
NSC 202705 had an IC50 of 55 PM, whereas verapamil exhibited an IC50 of 57 PM. 
However, we additionally found that this urea was weakly fluorescent at 450 nm, and it 


















can be observed on the same fluorescence channel as PBGT. This made it difficult to 
determine its relative potency because it was not possible to distinguish the signal from 
PBGT from the signal due to the urea. In addition, because intrinsic fluorescence 
contributes to the observed activity, the IC50 for this compound appears to be more potent 
than its actual value. Because a blue fluorescent urea such as NSC 202705 might be 
problematic for analysis with PBGT, we designed a potentially orthogonally fluorescent 
urea for further analysis with PBGT. With the assistance of KU Synthetic Chemical 
Biology Core, we generated a green fluorescent urea (GF urea, Figure 2.12a), derived 
from the NBD fluorophore, that is very similar in structure to NSC 202705. We confirmed 
that this compound, termed the green fluorescent urea (GF-urea), did not spectrally 
overlap with PBGT, and this compound also inhibited the cellular efflux of PBGT (Figure 
2.11b). Additionally, as shown in Figure 2.12c, the IC50 of the GF-urea was measured to 









(A)      (B)                                        
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Figure 2.12. (A) The structure of the GF-urea analogue of NSC 202705. (B) Analysis of 
the GF-urea in the PBGT/Jurkat assay by flow cytometry. (C) Dose response of the GF-
urea compared with verapamil. 
 
 We hypothesized that this green fluorescent analogue of NSC 202705 could 












































































PBGT uptake in Jurkat cells


















compounds. In addition, since it is orthogonally fluorescent when compared to PBGT, 
both of these compounds can be simultaneously analyzed in cells by confocal microscopy. 
To qualitatively validate that this compound can overcome cellular efflux and promote the 
accumulation of PBGT, HeLa cells were treated with 25 PM urea and 1 PM PBGT. 
Confocal micrographs of HeLa cells treated in this way are shown in Figure 2.13. 
                         PBGT (1 PM)         GF-Urea (25 PM)       PBGT + GF-Urea 
                         
                        
                        
Figure 2.13. Confocal and DIC images of HeLa cells treated with PBGT (1 PM, left), the 
GF-urea (25 PM, center), and both of these compounds (right). The top row shows 
excitation at 405 nm with emission from 420-480 nm (blue fluorescent). The middle row 
shows excitation at 488 nm with emission from 500-600 nm (green fluorescent). The 
bottom row shows DIC images. 
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 Confocal images of HeLa cells treated with 25 PM green fluorescent urea 
demonstrated that this compound promotes cellular uptake of PBGT. Another interesting 
finding from these images was the unique localization of the urea compound. This 
compound appeared to be either aggregating or localizing in a particular subcellular 
compartment. We hypothesized that this localization might be related to the cellular 
accumulation of PBGT, but the involvement of P-gp would require further studies of 
possible mechanisms of inhibition. 
 
2.4.2 Investigation of mechanisms of inhibition of P-gp by diaryl ureas 
 As previously discussed in chapter one, fluorescent fusion proteins can provide a 
valuable method to probe biological interactions. To further investigate possible 
mechanisms of inhibition of P-gp by diarylurea compounds, we employed the use of 
pHaMDR-EGFP, a plasmid encoding P-gp fused to enhanced green fluorescent protein. 
Because this fusion protein is green fluorescent, we could not use the green fluorescent 
urea as a probe. Instead, we used the original blue fluorescent hit, NSC 202705, to 
examine colocalization with P-gp, which is normally expressed on the plasma membrane.  
For these studies, we transiently transfected PC-3 prostate cancer cells, which do 
not appear to express P-gp, with pHaMDR-EGFP. Cells were treated with 10 PM NSC 
202705 and analyzed by confocal microscopy. Although NSC 202705 exhibited relatively 
weak fluorescence when examined by flow cytometry methods, it proved to be a bright 
fluorescent probe when analyzed by confocal microscopy. Because of this, we could 
assess its accumulation in cells that express green fluorescent P-gp. The images shown 
in Figure 2.14 revealed that there was not much of a difference in the concentration of the 
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urea in transfected cells that express P-gp compared with non-transfected cells, indicating 
that this urea is not likely to be a sensitive substrate of P-gp. We additionally did not notice 
any changes in the localization of P-gp when transfected cells were treated with NSC 
202705 (Figure 2.14). 
           202705 (10 PM)     pHaMDR-EGFP     202705 (10 PM) + pHaMDR-EGFP 
                          
                         
                        
Figure 2.14. Transfection of PC-3 cells with pHaMDR-EGFP in. Confocal laser scanning 
and DIC microscopy of PC-3 prostate cancer cells transiently transfected with pHaMDR-
EGFP and / or treated with 10 PM NSC 202705. The top row shows excitation at 405 nm 
with emission from 420-470 (blue fluorescent). The middle row shows excitation at 488 
nm with emission from 500-600 nm (green fluorescent). The bottom row shows DIC 
images. 
 
Although NSC 202705 did not appear to affect the localization of P-gp-EGFP, the 
localization of the compound suggested a possible explanation as to how this compound 
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might affect the uptake of PBGT. After a literature review, we discovered that the 
structurally similar diarylsulfonylureas have been shown to localize in mitochondria.41-42 
Furthermore, some quinazolinyl-diarylurea derivatives can decrease the mitochondrial 
membrane potential and disrupt mitochondria.43  
To see whether this particular diarylurea affects mitochondria, we treated cells with 
MitoTracker deep red, a fluorescent probe that specifically stains mitochondria. HeLa 
cells were treated with 100 nM MitoTracker deep red and 10 PM NSC 202705, incubated 
for 1 hour at 37 °C, and subsequently imaged with a confocal microscope. As shown in 
Figure 2.15a, some colocalization (shown in yellow) was observed between these 
compounds. Additionally, we found that cells treated with only MitoTracker exhibit healthy 
rod-shaped mitochondria, whereas cells treated with both MitoTracker and the urea 
exhibit an altered more spherical mitochondrial morphology, indicating potential 













                  DIC                    MitoTracker             NSC 202705                Overlay 
        
(B) 
                       MitoTracker only                             MitoTracker and NSC 202705 
        
Figure 2.15. Localization in mitochondria and effects of NSC 2020705 on these 
organelles. (A) Confocal laser scanning and DIC microscopy of HeLa cells co-treated with 
10 PM NSC202705 and 100 nM MitoTracker deep red. MitoTracker was excited at 635 
nm and the emission collected from 645-700 nm. NSC 202705 was excited at 405 nm 
and the emission collected from 420-470 nm. B) Confocal laser scanning of HeLa cells 
treated with only 100 nM MitoTracker (left image) and co-treated with 100 nM MitoTracker 
and 10 PM NSC202705 (right image). 
 
 To further investigate the effects of diarylureas on mitochondria, HeLa cells were 
treated with mitotracker deep red and the urea compounds NSC 202705, 46492, 216183, 




MitoTracker & NSC 46492     MitoTracker & NSC 216183 
          
    MitoTracker &  GF Urea         MitoTracker & NSC 202705 
         
Figure 2.16. Mitochondrial disruption observed upon treatment with all urea hits. Confocal 
laser scanning micrographs of HeLa cells treated with 100 nM MitoTracker deep red 
without and with each urea hit from our screen and the GF urea analogue. 
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For each well co-treated with a diarylurea, the native rod-like morphology of the 
mitochondria appeared to be lost. The mitochondria become fragmented, a phenotype 
often observed in the early stages of apoptosis.44 Treatment with each of these 
diarylureas can change mitochondrial morphology and potentially disrupt mitochondrial 
function. Based on other studies that have shown that nanoparticles that disrupt 
mitochondria can affect P-gp through depletion of ATP,45 we hypothesized that disruption 
of mitochondria by the GF-urea could potentially lead to plunging ATP levels within the 
cell and consequent inhibition of ATP-dependent P-gp-mediated efflux.   
 To test this hypothesis, we worked with the High Throughput Screening Laboratory 
at KU to analyze the effect of NSC 202705 on cellular ATP levels in both HeLa and Jurkat 
cells using a luciferase reporter assay. Cells were treated with CellTiter-Glo and varying 
concentrations of NSC 202705 from 0 to 80 PM. Following incubation for 1 h or 4 h at 
37 °C, ATP-dependent luminescence was measured. Cellular ATP levels were then 
interpolated from an ATP standard curve (figure 2.17) 
 














Effect of NSC 202705 on ATP levels in Jurkat cells
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Figure 2.17. Effects of NSC 202705 on cellular ATP levels. (A) Jurkat lymphocytes were 
treated with CellTiter-glo and increasing amounts of NSC 202705. (B) HeLa cells were 
treated with CellTiter-glo and increasing amounts of NSC 202705. 
 
Surprisingly, no correlation between ATP-levels and the concentration of NSC 202705 
in either cell line was observed in glucose-rich media. ATP-levels remained constant 
when dosed with high concentrations of NSC 202705, indicating that the depletion of 
cellular ATP was not the mechanism of inhibition. However, this assay was run in high-
glucose media, and the ATP consumed in this assay did not necessarily originate from 
mitochondria. This assay was ran again in media supplemented with low glucose and D-
galactose supplemented media to further determine whether NSC 202705 affects ATP 

























Figure 2.18. Effects of NSC 202705 on cellular ATP levels in glucose deficient media. (A) 
HeLa cells were treated with CellTiter-glo and increasing amounts of NSC 202705 in 
galactose and low glucose supplemented media. (B) Jurkat Lymphocytes were treated 
with CellTiter-glo and increasing amounts of NSC 202705 in galactose and low glucose 
supplemented media. 
 
These studies showed that NSC 202705 was not a potent inhibitor of ATP production 
in glucose deficient media. However, high concentrations of NSC 202705 slightly 
decreased cellular ATP levels when compared to the negative control. Further studies 
are needed to determine how/if these two phenotypes are linked and might confirm that 
these compounds represent a novel chemotype and mechanism of action as cellular 
efflux inhibitors. 








































































2.5  Conclusions  
In summary, a high-content assay utilizing flow cytometry and a fluorescent mimic 
of Taxol was developed with an automated screening platform to detect inhibition of 
cellular efflux. A pilot screen of 1584 diverse small molecules was performed to identify 
inhibitors of efflux involving P-gp. From this phenotypic screen, we identified 23 
compounds that increase the cellular fluorescence of Jurkat lymphocytes. Two families 
of compounds identified from the primary screen, phenothiazines and carbazoles, are 
already well studied P-gp inhibitors and substrates, providing evidence that this assay 
can identify inhibitors of P-gp. Additionally, a novel chemotype of diarylureas, carbamates, 
and amides was found to inhibit cellular efflux. The diarylureas were studied further to 
determine a possible mechanism of inhibition. Through the use of confocal laser scanning 
microscopy, we found that these diarylureas do not appear to be substrates of P-gp, nor 
do they appear to bind directly to P-gp. Further studies found that these diarylureas 
appear to disrupt the structures of mitochondria and can slightly decrease ATP levels in 
cells supplemented with glucose deficient media. The mechanism of cellular efflux 
inhibition for these compounds still remains to be determined, however, further studies to 
investigate how/if these two phenotypes are related could lead to a novel method to 
modulate P-gp mediated cellular efflux. 
 
2.6  Experimental section 
General: Chemicals were obtained from Sigma Aldrich or the National Cancer Institute 
(NCI) and were used without further purification. PB-Gly-Taxol was prepared by Dr. Bailin 
Lei, a former postdoctoral fellow in the Peterson laboratory, as previously reported.15 The 
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GF Urea analogue of NSC 202705 was prepared by the KU Synthetic Chemical Biology 
Core.  
 
Cell culture: Jurkat lymphocytes, ATCC TIB-152, were cultivated in Roswell Park 
Memorial Institute (RPMI) 1640 medium. HeLa cells, ATCC CCL-2, were cultivated in 
Dulbecco's Modified Eagle Medium (DMEM) medium. PC-3 cells, a gift from Dr. Matthew 
Levy, were cultivated in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 
(DMEM/F-12) medium. All media was supplemented with Fetal Bovine Serum (FBS, 10%), 
penicillin (100 units/mL), and streptomycin (100 μg/mL). Cells were maintained in a 
humidified 5% CO2 incubator at 37 °C. 
 
Confocal Microscopy: Cells were seeded on an 8-well Ibidi μ-slide (300 μL, 20,000 
cells/well) 24 hours prior to analysis with the confocal microscope. All compounds were 
dosed in 1:1000 dilutions in complete medium (0.1% DMSO). This media was then 
swapped with the media in the Ibidi μ-slide. After dosing, cells were incubated for 1 hour 
(unless otherwise noted) at 37 °C then analyzed on a Leica SPE2 confocal laser scanning 
microscope. Fluorophores were excited at 405 nm, 488 nm, and/or 635 nm. Emitted 
photons were collected from 420-470 nm, 500-600 nm, and/or 645-700 nm unless 
otherwise noted.  
 
Flow Cytometry: Cells were analyzed using a Beckman Coulter CytoFLEX S (B2-R0-
V2-Y2) flow cytometer. 405 nm and 488 nm diode lasers were used to excite the 
fluorophores. Emitted photons were collected with 450/45 nm PB filter or 525/40 nm FITC 
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filter. Flow speed = fast, backflush = 3 s, mixing time = 3 s, and cells were collected until 
5000 cells were counted or until a time limit of 120 s was reached. 
 
Comparison of PBGT to calcein-AM: 200 μL of Jurkat lymphocytes (7.5 × 105 cells/ml) 
in RPMI media were seeded in 15 wells of a 96 well plate (200 μL/well). 10 mL of the 
Jurkat lymphocytes were split into two conical tubes (5 mL each). To one tube, 5 μL of 1 
mM PBGT in DMSO was added to afford a final concentration of 1 μM. To the other tube, 
5 μL of 0.25 mM Calcein-AM in PBS was added to afford a final concentration of 0.25 μM 
Calcein-AM. 200 μL of each solution was seeded in 18 wells of a 96 well plate (9 wells 
each). 0.2 μL of 25 mM and 100 mM verapamil were dosed in triplicate in wells containing 
1 μM PBGT, 0.25 μM calcein-AM, and only cells. 9 wells were left with only 1 μM PBGT, 
0.25 μM Calcein-AM, or 0.1% DMSO. Cells were incubated for 1 hour at 37 °C and 
subsequently analyzed with a Beckman Coulter CytoFLEX S (B2-R0-V2-Y2) flow 
cytometer. 5000 cells were counted for each sample. Photons emitted by PBGT were 
collected after passing through a Pacific Blue filter (450/40). Photons emitted by calcein-
AM were collected after passing through a FITC filter (520/40).  
 
Primary screening assay by flow cytometry: Jurkat lymphocytes (7.5 × 105 cells/ml) in 
RPMI media (25 mL) were placed in a 25 mL integra multichannel reservoir. 25 μL of 1 
mM PBGT in DMSO was added to the reservoir for a final concentration of 1 μM (0.1% 
DMSO). Solution was mixed by pipetting then transferred to a 96 well plate (200 μL/well) 
using an Integra ASSIST PLUS pipetting robot. Library compound (0.5 μL,10 mM in 
DMSO) was transferred from the NCI diversity set VI library plate to the assay plate for a 
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final concentration of 25 μM (0.35% DMSO). Compounds were transferred into the same 
well on the assay plate as the well it is stored on the library plate to encode what is in 
each assay well. Positive controls (25 and 100 μM verapamil) and negative controls 
(DMSO) were added manually. Plates were incubated for 1 hour at 37 °C then analyzed 
with a Beckman Coulter CytoFLEX S (B2-R0-V2-Y2) flow cytometer. 5000 cells were 
counted for each sample. Library compounds were tested as singlets while controls were 
tested in triplicate. Photons emitted by PBGT were collected after passing through a 
Pacific Blue filter (450/40). To assess the intrinsic fluorescence of library members the 
same assay was ran, but PBGT was not added to the reservoir. 
 
Generation of dose response curves: Jurkat lymphocytes (7.5 × 105 cells/ml) in RPMI 
media (25 mL) were placed in a 25 mL integra multichannel reservoir. 25 μL of 1 mM 
PBGT in DMSO was added to the reservoir for a final concentration of 1 μM (0.1% DMSO). 
Solution was mixed by pipetting then transferred to a 96 well plate (200 μL/well) using an 
Integra ASSIST PLUS pipetting robot. Inhibitors were dosed in duplicate in 1:1000 
dilutions to keep DMSO concentration constant. After dosing, plates were incubated for 
1 hour at 37 °C then analyzed with a Beckman Coulter CytoFLEX S (B2-R0-V2-Y2) flow 
cytometer. 5000 cells were counted for each sample. Photons emitted by PBGT were 
collected after passing through a Pacific Blue filter (450/40).  
 
Cellular uptake of PBGT mediated by the GF Urea: 200 μL of Jurkat lymphocytes (7.5 
× 105 cells/ml) in RPMI media were seeded in 12 wells of a 96 well plate (200 μL/well). 5 
mL of the Jurkat lymphocytes were placed in a 15 mL conical tube. 5 μL of 1 mM PBGT 
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in DMSO was added to afford a final concentration of 1 μM. 200 μL of the solution was 
seeded in 12 wells of a 96 well plate. 0.2 μL of 25 mM a verapamil in DMSO was dosed 
in triplicate to wells containing 1 μM PBGT and only cells. 0.2 μL of 10 mM and 25 mM 
GF urea in DMSO were dosed in triplicate to wells containing 1 μM PBGT and only cells. 
6 wells were left with only 1 μM PBGT and 0.1% DMSO. Cells were incubated for 1 hour 
at 37 °C then analyzed with a Beckman Coulter CytoFLEX S (B2-R0-V2-Y2) flow 
cytometer. 5000 cells were counted for each sample. Photons emitted by PBGT were 
collected after passing through a Pacific Blue filter (450/40).  
 
Transient transfection of PC-3 cells with pHaMDR-EGFP: This transfection assay was 
adapted from the previously reported protocol.15 PC-3 cells in DMEM/Ham’s F-12 medium 
were seeded into a 8-well Ibidi μ-slide (300 μL, 20,000 cells/well) and incubated for 16 h 
at 37 °C. Plasmid pHaMDR-EGFP (2 μg, a gift from Dr. Michael M. Gottesman, NCI) was 
incubated in 200 μL serum free DMEM/Ham’s F-12 medium at 22 °C with the DNA 
transfection reagent X-tremeGENE HP (2 μL, Roche) for 30 minutes. After incubation, 20 
μL of the DNA complex was added to each desired well of the Ibidi μ-slide. The slide was 
incubated for another 48 hours then washed with complete medium, treated with probes 
and imaged using the confocal microscopy protocol.  
 
ATP-Depletion analysis: Jurkat cells (4000 cells/well) and Hela cells (3000 cells/well) in 
DMEM media (high glucose, low glucose, or galactose supplemented), were exposed to 
various concentrations of NSC 202705 (0, 0.001, 0.01, 0.1, 1, 10, 20, 40 and 80 PM) for 
1h, 4h, and/or 24h at 37 °C, 5% CO2. Cell-Titer Glo (promega) was added to the cells 
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and to a freshly plated ATP concentration curve (0,0.01, 0.1, 1, 10, 100, 1000, 2000 and 
5000 nM), After 10 min of incubation at room temperature, luminescence was read using 
Perkin Elmer Enspire. ATP levels were interpolated from the ATP standard curve. 
 
Compound characterization data 
1-(4-chlorophenyl)-3-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)urea (GF Urea):  
 
 
1H NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H), 9.69 (s, 1H) 8.76 (d, J = 8.6 Hz, 1H), 
8.20 (d, J = 8.5 Hz, 1H), 7.54 (d, J = 8.7 Hz, 2H), 7.41 (d, J = 8.8 Hz, 2H). 13C NMR 
(126 MHz, DMSO-d6): δ 151.5, 145.9, 143.8, 137.7, 137.1, 136.4, 129.4, 129.1, 128.7, 
127.3, 120.7, 120.3, 110.6. HRMS calculated for C13H8ClN5O4 (M-H)+ 331.98; found 
331.99 (TOF MS ES+). 
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Plate map and raw screening data 





4860 A02 18473 125 21666.3 1875.9 90% 
4860 B02 30041 136 21481.9 1774.3 89% 
4860 C02 38968 129.2 20639.6 1733.8 89% 
4860 D02 41833 125 19459.4 1701.8 90% 
4860 E02 42633 149 20297.4 1681.3 88% 
4860 F02 47881 145 17636.6 1618.8 90% 
4860 G02 48231 138 16775.5 1613.1 89% 
4860 H02 51787 145 17232.4 1934.6 87% 
4860 A03 54260 150 20823.7 1627.4 88% 
4860 B03 65248 150 22722.5 1568.9 88% 
4860 C03 75071 131 20601 1569.6 88% 
4860 D03 113532 145 19269.7 1574.3 90% 
4860 E03 122276 150 18469.4 1541.1 89% 
4860 F03 123797 150 16924 1512.6 89% 
4860 G03 135857 142 16823.8 1511.9 90% 
4860 H03 148304 144 15897.9 1514.6 89% 
4860 A04 149877 122 20561.8 1555.3 89% 
4860 B04 173969 146 20218.2 1581.1 89% 
4860 C04 200686 138 20240.2 1537.4 89% 
4860 D04 679449 136 18726.6 1509 89% 
4860 E04 4135 190 19867.8 1514.4 88% 
4860 F04 4426 191 16973.3 1525.5 89% 
4860 G04 4936 165 16471.6 2249.4 89% 
4860 H04 5784 180 15777 1519.5 89% 
4860 A05 7606 158 20187.5 1551.6 89% 
4860 B05 7950 185 21227.6 2753 88% 
4860 C05 9441 190 22006.9 1528.1 89% 
4860 D05 9489 182 20624.1 1524.6 90% 
4860 E05 10427 188 19093.5 1499.8 90% 
4860 F05 10772 178 17056.4 1472.4 89% 
4860 G05 11128 197 16119.2 1502.4 88% 
4860 H05 11141 163 15830.7 1475.2 88% 
4860 A06 11470 182 21422.6 1535.9 88% 
4860 B06 12588 158 21394.9 1513.9 88% 
4860 C06 13213 187 21167.1 2069.1 89% 
4860 D06 14767 185 19833.1 1539 89% 
4860 E06 14771 198 17958.1 1482.7 88% 
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4860 F06 15133 171 16294.8 1462.8 89% 
4860 G06 15776 193 16307.1 3709.1 87% 
4860 H06 16021 164 16379.5 1502.3 89% 
4860 A07 16162 165 21916.6 1940.6 89% 
4860 B07 16631 154 21150.1 1534.9 89% 
4860 C07 16646 180 21504.9 1518.5 88% 
4860 D07 16873 190 20999.6 1615.9 89% 
4860 E07 17796 162 17965.6 1538 89% 
4860 F07 18415 191 19270.3 1517.8 89% 
4860 G07 19219 198 21875.7 7996.8 88% 
4860 H07 19848 188 16824.8 2149.1 88% 
4860 A08 20559 193 20519.1 1610.9 88% 
4860 B08 22847 171 21096.8 1527 87% 
4860 C08 23225 156 20930.4 1550.6 87% 
4860 D08 27389 180 20532.7 1517.9 88% 
4860 E08 27626 194 17621.5 1502.3 88% 
4860 F08 28011 154 17043.7 1490 89% 
4860 G08 28837 161 15949.8 1479.3 88% 
4860 H08 29193 184 15580.9 1479.9 88% 
4860 A09 29629 163 21895.6 1521.6 87% 
4860 B09 29851 155 20681 1543.9 89% 
4860 C09 29874 185 20315.2 1499 87% 
4860 D09 31712 174 19707.4 1489.7 88% 
4860 E09 34012 157 17936.1 1486.4 88% 
4860 F09 34210 157 16231.1 1485.9 88% 
4860 G09 34794 160 14944.3 1449.1 89% 
4860 H09 34983 191 15679.4 1466.5 88% 
4860 A10 35534 181 21323.1 1542.1 88% 
4860 B10 35679 180 21431.3 1742.9 88% 
4860 C10 37408 166 21358.2 1482.4 88% 
4860 D10 37883 187 20436.6 1472.3 88% 
4860 E10 40817 193 37130.1 15733.8 88% 
4860 F10 40840 156 15948.1 1534.5 88% 
4860 G10 41331 199 15532.2 1476.2 89% 
4860 H10 42021 197 15805.6 1554.9 88% 
4860 A11 42028 158 21502.4 1536.3 89% 
4860 B11 42231 182 22542.1 2345.6 88% 
4860 C11 42774 172 21060.6 1493.4 88% 
4860 D11 43013 172 20384.2 1484.1 87% 
4860 E11 43512 200 19452.8 1568.6 88% 
4860 F11 43546 156 16078.7 1465.8 89% 
4860 G11 43805 184 14768.6 1492.3 87% 
4860 H11 44680 155 23628.7 1599.3 86% 
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4861 A02 44819 199 20787.6 1608.6 92% 
4861 B02 45117 181 21830.4 1764.4 93% 
4861 C02 45641 190 20587.7 1610.1 91% 
4861 D02 45719 177 20766.4 1526.1 93% 
4861 E02 46273 198 21035.4 1514.8 92% 
4861 F02 47496 188 19066.7 1511.1 92% 
4861 G02 48422 173 16545.4 1620.2 93% 
4861 H02 49252 156 16465.6 1481.2 92% 
4861 A03 50751 186 22187.1 1772.6 92% 
4861 B03 50858 182 20953.6 1506.1 92% 
4861 C03 51093 180 19629.6 1490.8 92% 
4861 D03 53506 179 20165.6 1496.7 93% 
4861 E03 54834 181 19107.4 1621.3 92% 
4861 F03 55459 189 18135 1491.8 92% 
4861 G03 55573 171 16567.3 1508.8 92% 
4861 H03 55957 198 28480.1 1779.6 90% 
4861 A04 56914 184 21108.6 1549.1 91% 
4861 B04 57741 174 26434.2 7339 92% 
4861 C04 57890 194 20202.3 1574.8 92% 
4861 D04 60239 192 20399.7 1552.4 92% 
4861 E04 60373 183 19514.1 1498.6 92% 
4861 F04 60377 169 17984.7 1572.9 93% 
4861 G04 60530 151 16748.3 1467.8 93% 
4861 H04 60548 175 15933.8 1479.5 92% 
4861 A05 62129 184 19107.3 1802.1 90% 
4861 B05 62318 194 21403.8 1530.9 92% 
4861 C05 62511 190 20642.4 1506.1 92% 
4861 D05 62609 195 20154.1 1834.8 92% 
4861 E05 62840 171 17673.9 1530.5 91% 
4861 F05 63311 189 20039.5 1973.1 93% 
4861 G05 63314 189 18154.6 1831 91% 
4861 H05 64952 154 28689.1 13602.2 92% 
4861 A06 66241 200 21706.4 1943.9 92% 
4861 B06 67307 186 22721.7 1600.1 92% 
4861 C06 68657 178 20757.3 1565.7 92% 
4861 D06 70717 165 20834.6 1616.8 92% 
4861 E06 72292 198 1031910 867511.6 92% 
4861 F06 73482 179 21538.2 3129.1 91% 
4861 G06 75585 171 16624.6 1767.3 91% 
4861 H06 75786 159 16306.8 1663.6 91% 
4861 A07 75846 157 20745.6 1633.7 92% 
4861 B07 77422 200 22083 2026.5 92% 
4861 C07 77913 194 21591.1 1699.2 92% 
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4861 D07 78609 173 19097.8 1535.8 90% 
4861 E07 78999 173 18833.1 1500.8 92% 
4861 F07 79010 161 16852.6 1476.7 92% 
4861 G07 79582 196 15933.5 2248.6 91% 
4861 H07 80807 198 15453.5 1581.8 92% 
4861 A08 81462 182 21029.1 1602.4 92% 
4861 B08 82339 189 21680.5 1586.3 92% 
4861 C08 82769 172 21325.9 1547.1 91% 
4861 D08 83076 151 19216.8 1508 91% 
4861 E08 83237 191 18220.4 1651.3 91% 
4861 F08 83339 191 16903.4 1542.1 91% 
4861 G08 83345 199 15453 1478.2 91% 
4861 H08 84200 169 15300 1474.2 91% 
4861 A09 85331 177 20172.8 1575 92% 
4861 B09 88882 196 19558.2 1625.5 91% 
4861 C09 89720 151 20573.7 1553 92% 
4861 D09 91438 194 20013.6 1531.5 91% 
4861 E09 92264 176 18160.4 1808.9 91% 
4861 F09 92753 187 16749 1507 92% 
4861 G09 93260 157 15050.3 1519.8 91% 
4861 H09 96979 152 15390.7 1585.5 91% 
4861 A10 97090 151 20306 1610.4 91% 
4861 B10 97104 192 54052.4 36748.2 91% 
4861 C10 97538 157 23531.8 3319 91% 
4861 D10 99756 196 20473.8 1815.8 91% 
4861 E10 100729 162 18299.4 1642.5 91% 
4861 F10 102025 198 16888.8 1682.7 91% 
4861 G10 102509 180 15295.2 1870.2 91% 
4861 H10 104969 195 15744 1659.6 90% 
4861 A11 106045 187 20479.6 1625.5 92% 
4861 B11 106261 179 21164.4 1605.2 90% 
4861 C11 108655 167 21114.1 1894.8 91% 
4861 D11 109176 168 19973.7 1550.3 91% 
4861 E11 109231 197 18501.5 1539.8 91% 
4861 F11 109528 195 18932.8 4358 91% 
4861 G11 109813 187 24246.8 1630.9 90% 
4861 H11 20586 192 14651 1535.1 91% 
4862 A02 109885 181 21512.8 1707.6 91% 
4862 B02 111107 184 21617.8 1729.6 91% 
4862 C02 116565 199 22980.3 1725.5 91% 
4862 D02 117386 170 21234.2 1634.6 92% 
4862 E02 118832 191 21613.9 1714.8 92% 
4862 F02 119969 188 21565 1918.9 92% 
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4862 G02 120312 196 20572.4 1641.2 92% 
4862 H02 122131 173 116684.6 120008.1 91% 
4862 A03 123458 193 21361.4 5153 90% 
4862 B03 125197 193 21270.6 2279.2 91% 
4862 C03 127216 162 21218.7 2067.8 92% 
4862 D03 127458 195 22709.3 3281.7 91% 
4862 E03 127947 199 21530 1885.9 90% 
4862 F03 128068 183 22190.4 2778.4 91% 
4862 G03 131982 194 20979.5 1756.8 92% 
4862 H03 134577 164 20787.8 1761.4 90% 
4862 A04 134580 167 21305.2 1803.2 92% 
4862 B04 134784 182 21174.6 1825.4 91% 
4862 C04 134785 197 21317.5 1748.8 91% 
4862 D04 135351 151 21269.8 1729.7 91% 
4862 E04 136065 191 21150 1793.7 91% 
4862 F04 145180 167 21071.1 1683.6 92% 
4862 G04 147829 186 19816.3 1740.8 91% 
4862 H04 150982 188 34356.2 4433.4 90% 
4862 A05 151901 189 21355.4 1830.4 92% 
4862 B05 152632 174 20747 1727.5 91% 
4862 C05 154316 153 20549 1739.5 92% 
4862 D05 154718 183 21067.5 1952.9 91% 
4862 E05 155196 169 21585.4 1839.6 91% 
4862 F05 155698 200 30637.5 8143.9 90% 
4862 G05 155703 196 20676.2 2077.3 90% 
4862 H05 156571 171 20283.8 1778.5 91% 
4862 A06 160005 168 21207.9 1756 92% 
4862 B06 162292 196 20251.8 1787.9 91% 
4862 C06 162915 197 21114.4 1950.1 92% 
4862 D06 163104 198 22551.4 1785.7 92% 
4862 E06 163158 165 21575 1716.7 90% 
4862 F06 163920 184 17914.8 1912.6 89% 
4862 G06 164965 187 20571.8 1707 91% 
4862 H06 166900 156 20870.4 1693.7 91% 
4862 A07 169458 185 21099 1740.2 90% 
4862 B07 169566 151 20104.4 1755.6 90% 
4862 C07 173101 193 20359.3 1769.4 90% 
4862 D07 176324 195 20552.1 1747.5 91% 
4862 E07 177952 156 20232 1702.8 90% 
4862 F07 191029 183 20765.9 1702.3 90% 
4862 G07 194242 161 19880.2 1673.3 89% 
4862 H07 194243 176 20084.1 1711.3 90% 
4862 A08 195031 185 21540.3 1772.9 91% 
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4862 B08 203065 191 21973.5 1690.3 90% 
4862 C08 206630 172 20531.7 1734 90% 
4862 D08 227309 189 21463.3 1879.3 90% 
4862 E08 234764 196 19978.9 1713.6 90% 
4862 F08 246415 200 18536.3 1616.4 79% 
4862 G08 269905 188 20202.4 1692.7 89% 
4862 H08 272275 159 23290.3 4030.3 90% 
4862 A09 276369 182 22873.4 1789.3 91% 
4862 B09 278741 177 20326.3 1726.9 89% 
4862 C09 279834 187 21651.2 1752 89% 
4862 D09 284701 152 20691.6 1744.8 90% 
4862 E09 287065 178 19573 1731.1 89% 
4862 F09 287495 182 20525.6 1713.9 90% 
4862 G09 288686 189 18939.5 1789.8 89% 
4862 H09 295701 189 20187.9 1866.2 89% 
4862 A10 303244 199 28558.1 4838.1 89% 
4862 B10 303603 200 21169.4 1945.8 90% 
4862 C10 303800 171 21038.1 1752.2 90% 
4862 D10 304902 186 20637 2650.8 90% 
4862 E10 311723 189 20545.9 1831.8 89% 
4862 F10 321484 165 20722.6 1759.7 89% 
4862 G10 331198 155 20130.1 1735.8 89% 
4862 H10 331208 175 19588.3 1746.1 90% 
4862 A11 335649 166 21973.7 1785.6 89% 
4862 B11 338205 175 21280.8 1750.7 90% 
4862 C11 339578 199 26504.6 10117.3 84% 
4862 D11 341902 178 20732.4 1796.9 89% 
4862 E11 342460 183 20641.6 1917.1 90% 
4862 F11 344494 175 28250.1 3016.5 87% 
4862 G11 351110 183 19973.2 1809.6 88% 
4862 H11 361056 198 20404.1 1778.3 89% 
4863 A02 366808 197 19565.8 1632.2 91% 
4863 B02 370387 161 18953.2 1564.7 91% 
4863 C02 372063 191 19949.9 2476.4 90% 
4863 D02 407282 190 18609.6 1538.2 90% 
4863 E02 513815 178 18838 1518.9 89% 
4863 F02 650438 179 52841.4 29379.8 88% 
4863 G02 664971 169 18342.4 1494.1 92% 
4863 H02 672441 158 18854.1 1474.8 91% 
4863 A03 1451 239 19901.8 1584.1 90% 
4863 B03 1620 215 17904.3 1561.8 92% 
4863 C03 1751 224 18774 1527.2 92% 
4863 D03 2561 240 18957.5 1523.6 90% 
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4863 E03 2805 246 42000.1 4382.7 87% 
4863 F03 3001 214 19579.6 1483 90% 
4863 G03 4263 225 18623.9 1475.1 91% 
4863 H03 4921 214 18011.1 1487.8 91% 
4863 A04 5995 213 18064.1 1579.9 86% 
4863 B04 6866 232 19786.1 1552.7 91% 
4863 C04 6910 250 19901.8 1552.9 89% 
4863 D04 8090 247 19009.7 1601.4 91% 
4863 E04 8179 203 18730.4 1498.7 89% 
4863 F04 8481 208 17387.6 1519.5 91% 
4863 G04 8813 238 18934.2 1484.4 90% 
4863 H04 9064 204 19309.6 1482.8 90% 
4863 A05 9341 237 19032 1613.5 90% 
4863 B05 9358 226 14857.5 1362.6 89% 
4863 C05 9461 202 18464.8 1530.5 90% 
4863 D05 10091 240 36115.1 15823.3 89% 
4863 E05 10416 243 20971.7 4384.7 71% 
4863 F05 10428 204 18415.1 2131.6 90% 
4863 G05 10995 241 17622.7 1828.7 90% 
4863 H05 11149 235 14865.3 1708.4 89% 
4863 A06 11150 235 16403.3 1804 89% 
4863 B06 11826 228 18597.6 1765.1 85% 
4863 C06 11891 225 19463.9 1752.9 90% 
4863 D06 11991 226 19886.6 1586.1 89% 
4863 E06 13653 218 17816.9 1565.2 90% 
4863 F06 13974 247 14053.8 1744.2 92% 
4863 G06 14304 222 15054.5 1720.4 89% 
4863 H06 14540 219 17651.1 1727.8 90% 
4863 A07 15362 227 18044.5 1800.1 91% 
4863 B07 15364 242 17717.4 1647.9 88% 
4863 C07 15372 235 56089.1 38670.3 90% 
4863 D07 15571 246 20461.7 3355.5 90% 
4863 E07 16416 234 19156.6 1928.3 88% 
4863 F07 16813 216 25841.5 1685.1 88% 
4863 G07 17129 242 18985.6 1667.7 89% 
4863 H07 19063 230 20054.9 1620.9 89% 
4863 A08 19096 222 20268.9 1791.1 88% 
4863 B08 19108 244 18561.6 1639.8 89% 
4863 C08 19115 217 18804.9 1783.7 88% 
4863 D08 19487 220 20335.4 1664.7 89% 
4863 E08 19637 226 30047.7 1588.2 90% 
4863 F08 20045 205 18735.6 1584.3 89% 
4863 G08 21034 237 19780.3 1634.3 89% 
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4863 H08 21678 232 14426.5 1272.6 87% 
4863 A09 22939 224 21373.5 2414.6 89% 
4863 B09 23123 240 20130.3 2127.9 91% 
4863 C09 23247 237 19638.2 1668.9 88% 
4863 D09 23248 227 19087.3 1658.3 90% 
4863 E09 23672 222 17537.2 1608.7 89% 
4863 F09 23895 221 19096 2074.5 89% 
4863 G09 23906 201 53528.5 38112.3 89% 
4863 H09 24035 227 15158.1 1750.6 89% 
4863 A10 25368 216 18086.8 1811.9 88% 
4863 B10 26744 238 63466.5 1781.9 86% 
4863 C10 27032 223 16405 5208.3 86% 
4863 D10 27628 208 17379.3 1781.6 86% 
4863 E10 28341 210 20643.4 4483.7 89% 
4863 F10 29471 213 19986.6 1698.3 89% 
4863 G10 29620 212 16605.7 1611 89% 
4863 H10 112975 191 17890.3 1746.3 89% 
4863 A11 173103 196 17756.3 1684.6 88% 
4863 B11 281639 156 17392.6 1659.5 88% 
4863 C11 365560 187 24941.2 1580.3 87% 
4863 D11 3961 228 21403.1 1775.6 84% 
4863 E11 9852 240 21750 3142.9 86% 
4863 F11 14303 222 17993.2 2186.5 88% 
4863 G11 21725 244 17033.9 1679.1 88% 
4863 H11 17339 213 18009 2198.1 88% 
4864 A02 31208 248 23950.1 6706.3 92% 
4864 B02 31664 233 21576.1 2500.6 91% 
4864 C02 31741 203 21613 2329.7 91% 
4864 D02 32838 202 21761.7 2316.4 90% 
4864 E02 33005 243 53316.4 16828.6 91% 
4864 F02 34488 239 23943.8 2920.3 89% 
4864 G02 34769 218 21150.4 2419.5 91% 
4864 H02 34774 230 20798.2 2389.3 90% 
4864 A03 34777 214 21830.3 2322.6 89% 
4864 B03 35676 220 21108.3 2480.4 90% 
4864 C03 35964 238 22127.9 2343.7 90% 
4864 D03 36425 241 20856.5 2323.3 90% 
4864 E03 36520 238 22038 2405.6 90% 
4864 F03 36582 219 20951.4 2353.7 89% 
4864 G03 37003 244 20390 2335.8 90% 
4864 H03 37812 212 25975.8 13721.9 88% 
4864 A04 38042 237 21295.1 2426.1 89% 
4864 B04 38490 249 29190.1 9767.4 86% 
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4864 C04 38743 248 21665.9 2362.8 91% 
4864 D04 38845 242 21682.4 2364.3 90% 
4864 E04 38983 224 25062.3 2395.5 90% 
4864 F04 39336 223 21230.4 2363.5 90% 
4864 G04 40467 224 15053.4 2007.9 87% 
4864 H04 40500 237 18733.3 2281.7 90% 
4864 A05 40614 224 22880.7 2403.2 90% 
4864 B05 40669 209 21446.5 2340.5 89% 
4864 C05 41092 215 21186.6 2465.9 79% 
4864 D05 42014 228 21856.1 2336.2 89% 
4864 E05 44688 232 21127.8 2464.6 90% 
4864 F05 45153 222 20755.6 2351.7 90% 
4864 G05 45291 214 20987.6 2670.5 83% 
4864 H05 46615 233 19032.7 2361.5 90% 
4864 A06 47617 248 21620.1 2417.4 89% 
4864 B06 47619 216 20433.3 2403.7 90% 
4864 C06 48964 210 21923.3 3478.7 91% 
4864 D06 49652 225 35827.9 3091.3 86% 
4864 E06 49701 230 19434.8 2397.9 90% 
4864 F06 50633 237 20239.1 2395.6 91% 
4864 G06 51331 238 18868.5 2548 91% 
4864 H06 51936 214 20074.6 2413.8 91% 
4864 A07 55770 206 21500.7 2396.6 89% 
4864 B07 56455 235 22595.8 2399.9 90% 
4864 C07 57103 235 28362.8 2329.9 88% 
4864 D07 57165 202 21730.7 2379.4 88% 
4864 E07 57318 225 21364.9 2477.6 89% 
4864 F07 57345 226 22697.4 2968.2 90% 
4864 G07 57794 219 20503.8 2455.4 90% 
4864 H07 58907 237 20637.2 2479.2 89% 
4864 A08 59776 220 23141.7 2422.7 88% 
4864 B08 60034 244 21739.8 2453.8 90% 
4864 C08 60266 228 21392.8 2440.9 89% 
4864 D08 60419 203 30584.1 5908.4 86% 
4864 E08 61888 207 21190.9 4323.8 86% 
4864 F08 61910 231 20768.7 2696.6 88% 
4864 G08 62665 205 23031.8 2671.1 89% 
4864 H08 63001 236 30501.8 5990.4 87% 
4864 A09 63865 244 22578.3 2910.9 88% 
4864 B09 63963 248 23573.3 5353.5 89% 
4864 C09 66837 230 21479.7 2607.7 89% 
4864 D09 67546 203 20933.6 2580.3 90% 
4864 E09 69421 250 22300.8 2586.2 90% 
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4864 F09 70534 240 18784.4 2379.5 89% 
4864 G09 73170 244 20960.8 2553.8 89% 
4864 H09 75241 247 20728.3 2536.8 89% 
4864 A10 75885 234 22219.6 2528.4 88% 
4864 B10 77596 244 21556.7 2453.3 88% 
4864 C10 78130 243 13096.5 1897.2 86% 
4864 D10 79139 246 176435.3 171734.6 81% 
4864 E10 79253 244 59332.5 49958.7 92% 
4864 F10 79538 205 38894 25119.9 88% 
4864 G10 80141 250 29702.8 17480.4 86% 
4864 H10 81018 242 29774.6 13818.5 88% 
4864 A11 81120 249 27328.5 15260.9 81% 
4864 B11 81213 237 26583.6 9231.1 90% 
4864 C11 81660 217 25379.7 5879 88% 
4864 D11 81703 224 27483.9 4227.3 66% 
4864 E11 83715 247 30633.9 3551.8 81% 
4864 F11 85179 220 22654.6 3910.9 89% 
4864 G11 85326 211 21635.5 3774.2 88% 
4864 H11 87352 212 21019.5 3625.4 89% 
4865 A02 87822 244 23757.8 2170.9 94% 
4865 B02 88811 212 27277.1 2164.9 93% 
4865 C02 88883 215 23413.9 2441.8 95% 
4865 D02 88962 210 22592.8 2185.1 94% 
4865 E02 88998 236 23302.1 2115.1 94% 
4865 F02 89249 224 22340.8 2110.2 94% 
4865 G02 89258 218 96456.4 80012.8 92% 
4865 H02 89723 232 22714 3157.9 95% 
4865 A03 91516 212 24813 2454.5 92% 
4865 B03 92207 208 21878.7 2121.3 93% 
4865 C03 92794 245 20941.6 1572 94% 
4865 D03 93817 227 22627.1 2181.9 94% 
4865 E03 96491 241 22712 2134.4 95% 
4865 F03 98683 211 21850.4 2131.5 94% 
4865 G03 98857 211 19600.1 2178.6 90% 
4865 H03 99796 230 23658.9 2358 94% 
4865 A04 100120 241 23405.4 2217.3 95% 
4865 B04 101266 219 19812.4 2157.6 95% 
4865 C04 101777 250 22188.4 2121.6 94% 
4865 D04 102086 237 26834.9 2112.4 94% 
4865 E04 102288 205 21812.2 2127.1 94% 
4865 F04 103770 213 22492.1 2108.3 94% 
4865 G04 103775 228 21596.2 2104.9 94% 
4865 H04 106208 248 10674.3 1410.7 92% 
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4865 A05 106282 249 19980.2 1766.4 94% 
4865 B05 106461 240 19797.3 1984.2 93% 
4865 C05 106506 224 88204.1 95867.1 89% 
4865 D05 106570 238 20722.9 2092.6 95% 
4865 E05 106863 242 21834 2125.3 94% 
4865 F05 108235 229 15610.8 1768.2 93% 
4865 G05 108750 250 24366 4067.9 93% 
4865 H05 108753 209 22883.8 5483.5 92% 
4865 A06 108972 223 23557.9 2202.8 94% 
4865 B06 109084 214 25517.4 2091.6 94% 
4865 C06 109086 228 39900.6 2804.2 93% 
4865 D06 109466 245 23061.2 3005.3 92% 
4865 E06 109719 204 22000.1 2185.5 95% 
4865 F06 111552 202 35444.5 6375.3 83% 
4865 G06 112677 240 34060.8 12955.8 95% 
4865 H06 114490 226 23006.4 2534.2 94% 
4865 A07 114831 243 23469.8 2220 94% 
4865 B07 117554 250 27835.8 2172.6 94% 
4865 C07 117741 217 22346.1 2188.8 94% 
4865 D07 117922 210 22757 2164.8 94% 
4865 E07 118723 239 36498.7 15296.2 94% 
4865 F07 120286 220 21937 2479.2 93% 
4865 G07 120307 227 36233.6 17366.1 93% 
4865 H07 120844 210 22149.5 2480.6 94% 
4865 A08 121781 240 22179.2 2307.5 93% 
4865 B08 122280 204 27079.5 6729.6 93% 
4865 C08 122297 239 23189.1 2330.6 93% 
4865 D08 122376 226 24271.9 2331.3 94% 
4865 E08 122987 212 22743.6 2211.1 94% 
4865 F08 123141 214 23152.8 2227.4 93% 
4865 G08 124146 245 22334.1 2233.2 93% 
4865 H08 125043 212 22136.4 2184 93% 
4865 A09 125727 226 23244.2 2244.9 93% 
4865 B09 126405 232 31137.1 1801.9 89% 
4865 C09 126757 220 20352.8 3521 93% 
4865 D09 128141 236 22909.5 2200.7 94% 
4865 E09 128737 210 30621.3 10278.5 93% 
4865 F09 128751 229 23806.4 2554.9 94% 
4865 G09 129260 241 23227.9 2745.1 93% 
4865 H09 130872 236 28113.6 4359.5 93% 
4865 A10 40383 226 22804.6 2515.9 93% 
4865 B10 42846 213 28702.2 3638.3 93% 
4865 C10 53710 204 23036.5 2391.7 93% 
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4865 D10 57670 230 26338.4 2857.6 89% 
4865 E10 62611 212 22767.2 3096.9 93% 
4865 F10 68982 231 19175.8 2221.7 92% 
4865 G10 70959 201 32224.2 2463.4 93% 
4865 H10 71795 246 700715.8 261600.7 20% 
4865 A11 101653 209 72173.8 47282.3 93% 
4865 B11 109174 241 39379.7 17166.9 92% 
4865 C11 42212 223 30027.1 8078.8 91% 
4865 D11 50405 202 28022.3 6789 93% 
4865 E11 50572 248 35475.8 7735.4 92% 
4865 F11 56906 214 27134.4 5888.6 93% 
4865 G11 113486 209 25635.1 4903.5 92% 
4865 H11 73054 234 22429.3 4440.2 90% 
4866 A02 131986 208 19117.1 1801.8 89% 
4866 B02 133195 229 18821.7 1759.6 88% 
4866 C02 133356 214 19331.8 1767.1 89% 
4866 D02 139257 235 21309.1 1853.9 85% 
4866 E02 140892 244 20537.6 1783.1 89% 
4866 F02 143348 243 21954.3 2150.6 88% 
4866 G02 144958 242 20030.1 1960.1 89% 
4866 H02 144982 226 21365.2 1804.8 88% 
4866 A03 149046 228 21060.8 1927.8 87% 
4866 B03 149286 236 29753.4 2050.4 88% 
4866 C03 150954 231 80699.8 1746.3 89% 
4866 D03 152551 236 22894.8 3860.1 89% 
4866 E03 153330 220 20323.4 2015 89% 
4866 F03 153365 249 20053.5 1824.5 90% 
4866 G03 153399 237 20280 2128.6 89% 
4866 H03 154295 231 20440 1794.2 90% 
4866 A04 156616 215 19642 1790.1 89% 
4866 B04 157767 211 18456.8 2760 89% 
4866 C04 157940 250 18391.2 1849.8 89% 
4866 D04 159031 223 16688.9 2067.5 87% 
4866 E04 163144 211 24313.9 9545.2 89% 
4866 F04 164208 220 20855.8 1885.1 89% 
4866 G04 164511 206 21110 1783.6 89% 
4866 H04 164678 203 20847.1 1880.8 90% 
4866 A05 165883 227 18475.4 1829.7 90% 
4866 B05 166583 219 19139.2 2465.8 89% 
4866 C05 170001 206 17351.4 1956.4 89% 
4866 D05 170578 245 19051.9 1761.6 89% 
4866 E05 170621 202 18800.4 1787.9 89% 
4866 F05 174027 212 19434.9 1897.2 90% 
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4866 G05 175412 238 20787.6 1762.9 90% 
4866 H05 175415 216 21393.1 2164.9 89% 
4866 A06 176765 217 19002.3 1887 90% 
4866 B06 177989 237 17818.3 2153.3 86% 
4866 C06 179818 214 20203.5 4562.2 88% 
4866 D06 182400 233 19919.4 2477.2 89% 
4866 E06 190336 244 19208.5 1783.1 89% 
4866 F06 193043 221 20275.9 2186.2 89% 
4866 G06 196148 201 19304.3 1756.6 89% 
4866 H06 197049 221 20492.6 1763.2 89% 
4866 A07 202883 203 17272.3 1833.1 90% 
4866 B07 204920 226 23539.9 1789.9 89% 
4866 C07 204976 212 17387.4 1818.7 90% 
4866 D07 205843 244 19096 2078 90% 
4866 E07 210816 243 18487.1 1729 89% 
4866 F07 215276 206 20534 2665.6 89% 
4866 G07 220030 217 20535.1 1754.4 90% 
4866 H07 227383 211 19657.3 1746.6 89% 
4866 A08 234945 223 17986.6 1749.9 89% 
4866 B08 236246 233 17936 1798.9 88% 
4866 C08 240502 206 17408.1 1762 88% 
4866 D08 255025 226 17733.8 1749.8 89% 
4866 E08 261037 201 19451.2 1733.6 90% 
4866 F08 261610 218 19339.8 1730.3 88% 
4866 G08 274905 221 20917.1 2224.8 89% 
4866 H08 277806 230 18467.5 1795.6 89% 
4866 A09 279895 236 17058 1765.3 89% 
4866 B09 282187 248 17574.1 1827.4 88% 
4866 C09 284234 245 17078.9 1737 88% 
4866 D09 288519 240 20021.9 1807.6 88% 
4866 E09 289090 246 18933.8 1767 89% 
4866 F09 289365 250 18472 1781.7 89% 
4866 G09 290307 210 20263.3 1866.4 90% 
4866 H09 292826 250 22188.5 2404.2 91% 
4866 A10 293334 210 17103.2 1792.1 89% 
4866 B10 293780 209 21553.4 1799 90% 
4866 C10 294154 212 17116.7 1885.6 89% 
4866 D10 294623 242 19846.8 1781.4 88% 
4866 E10 295404 230 18318.6 1759.9 89% 
4866 F10 298197 221 18457.1 2071.5 89% 
4866 G10 298793 233 18310.5 1743.9 89% 
4866 H10 301168 236 17058.3 2280.5 88% 
4866 A11 309971 242 17711.2 1829.4 89% 
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4866 B11 311074 226 17050.6 1761.6 89% 
4866 C11 311727 240 22833.1 2931.4 87% 
4866 D11 319034 229 16936.8 1754.4 89% 
4866 E11 321506 245 18009.1 1755.8 88% 
4866 F11 327693 248 18919.9 1731.8 88% 
4866 G11 329676 214 18248.3 1730.8 88% 
4866 H11 330497 206 18661.5 1783.3 89% 
4867 A02 332473 220 28181.3 2182.3 94% 
4867 B02 335048 239 27568.8 2123.8 93% 
4867 C02 338106 240 25379.1 4411.7 94% 
4867 D02 341074 241 26282.3 2117.1 94% 
4867 E02 343343 224 29616.2 3679.7 94% 
4867 F02 343344 204 24971.4 2621.5 94% 
4867 G02 343783 238 35638.2 14506 93% 
4867 H02 353451 243 25078.7 2297.3 93% 
4867 A03 357683 223 34276.3 6735.5 94% 
4867 B03 366807 223 27482.5 2209.6 93% 
4867 C03 367428 220 26717.7 2172.9 94% 
4867 D03 367487 205 26949.9 2197.9 94% 
4867 E03 370367 211 25391.8 2186.6 93% 
4867 F03 372134 243 25663.4 2183.6 94% 
4867 G03 372221 230 25017.2 2168.6 93% 
4867 H03 373427 245 23543 2131.1 93% 
4867 A04 373535 232 27347.8 2182.3 94% 
4867 B04 375392 210 26291.2 2249 94% 
4867 C04 375997 241 28856.2 2278.9 92% 
4867 D04 382059 220 26585.8 2183.7 92% 
4867 E04 403374 229 24595 2150.8 94% 
4867 F04 503425 202 26687.8 2190.2 93% 
4867 G04 509563 243 24363.4 2129.3 93% 
4867 H04 515893 238 24780.9 2306.4 91% 
4867 A05 601351 240 27028.6 2189.4 93% 
4867 B05 605333 223 22821.1 2214.5 89% 
4867 C05 622175 203 26213.8 2254.3 93% 
4867 D05 636717 250 43134.2 13017.1 92% 
4867 E05 637290 215 30620.8 3387.6 92% 
4867 F05 638080 220 25805.2 3023.3 92% 
4867 G05 638134 203 26134.5 2446.6 93% 
4867 H05 643150 222 28494.9 8772.4 93% 
4867 A06 645987 242 385275.1 56014.3 54% 
4867 B06 646976 233 27673.2 2521.6 92% 
4867 C06 659107 244 28137.9 3735.6 88% 
4867 D06 660300 249 26104.1 2295.1 93% 
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4867 E06 479 267 25592.6 2250.6 93% 
4867 F06 1847 262 23808.5 2235.2 93% 
4867 G06 3076 265 21591.6 2341.1 94% 
4867 H06 3193 270 24912.4 2264.9 92% 
4867 A07 3247 275 27629.8 2273.4 94% 
4867 B07 4429 296 26860 2278.9 92% 
4867 C07 5426 258 27958.6 2996.5 92% 
4867 D07 5564 275 26964.1 2216.7 92% 
4867 E07 6137 263 25996.8 2181.3 93% 
4867 F07 6145 286 32398.7 3843 93% 
4867 G07 6731 254 27627.2 2294.3 82% 
4867 H07 6821 289 33455.3 2305.3 90% 
4867 A08 6844 292 32071.3 2403.5 93% 
4867 B08 7218 293 89906.3 67872.4 91% 
4867 C08 7420 298 36996.4 2222.4 83% 
4867 D08 7572 278 27353.8 2807.7 92% 
4867 E08 7745 268 25343 2251.5 93% 
4867 F08 7962 284 23845.3 2206.3 90% 
4867 G08 9782 282 36872 2454.4 91% 
4867 H08 10173 278 64683.3 47267.4 92% 
4867 A09 10211 287 30558 2334.8 91% 
4867 B09 10768 255 28483.3 3074.9 93% 
4867 C09 11296 286 33354.6 2367.5 91% 
4867 D09 131388 209 26197.8 2241 91% 
4867 E09 148170 227 25796.9 2295 88% 
4867 F09 154587 219 25957 2241.8 93% 
4867 G09 159632 236 54350.6 33790.3 92% 
4867 H09 166547 229 26798.4 2695.1 91% 
4867 A10 294161 238 29946 2257.1 92% 
4867 B10 329284 212 47501.9 2286.1 91% 
4867 C10 343230 226 27842.3 2203.3 92% 
4867 D10 7867 294 29995.8 2329.9 92% 
4867 E10 8816 252 31051.4 2240.6 91% 
4867 F10 11023 268 24290.5 2198.2 85% 
4867 G10 11275 266 31263.8 2267.5 90% 
4867 H10 11643 288 48481.6 2349.9 91% 
4867 A11 306752 238 29115.6 2228.1 91% 
4867 B11 10865 260 28006.8 2246.9 91% 
4867 C11 379639 245 28506.1 3408.5 79% 
4867 D11 402843 244 26436.8 2204.5 92% 
4867 E11 403379 203 25307.8 2233.4 91% 
4867 F11 647136 238 28938.4 3255.4 92% 
4867 G11 11276 266 31599.1 2450.6 91% 
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4867 H11 11624 277 24422.1 2314.6 91% 
4868 A02 11664 295 193144.8 4174 85% 
4868 B02 11912 274 945765.6 958155.3 77% 
4868 C02 12028 286 111994.5 79605.3 94% 
4868 D02 12488 271 61867.6 29786.1 63% 
4868 E02 12633 275 42841.3 16004.7 92% 
4868 F02 12644 289 39124.4 11594.3 93% 
4868 G02 12646 267 36351.6 9985.2 93% 
4868 H02 13151 259 69867.8 9976.7 86% 
4868 A03 13248 290 34539.2 9393.2 91% 
4868 B03 13345 254 27583.7 6165.9 93% 
4868 C03 13434 269 28616.9 5888.3 93% 
4868 D03 13579 268 30011.7 5299.6 93% 
4868 E03 13658 264 33047.9 5264.9 93% 
4868 F03 13785 267 30087.4 4964 93% 
4868 G03 13800 254 29712.6 7344.6 92% 
4868 H03 14380 266 46454.4 5302.7 92% 
4868 A04 14396 284 33792.1 4979.4 93% 
4868 B04 14398 299 27368.1 4439.4 92% 
4868 C04 15358 293 24199.8 3203.5 93% 
4868 D04 15359 264 25507 4005.1 92% 
4868 E04 15784 266 504816.5 4213.5 89% 
4868 F04 17148 286 26311.5 3682.6 92% 
4868 G04 17362 266 33010.2 3728.6 91% 
4868 H04 17507 253 35709.2 4109.5 90% 
4868 A05 19125 276 24751.5 3850.1 93% 
4868 B05 19136 273 32805.3 6084.6 90% 
4868 C05 19141 288 28331 3734.7 92% 
4868 D05 19824 275 27323 5432.2 92% 
4868 E05 19962 274 33986.4 3614.2 92% 
4868 F05 21333 260 32453.4 4244.2 92% 
4868 G05 21603 290 32286.2 3569.4 85% 
4868 H05 21683 292 17229.3 2867.9 90% 
4868 A06 21709 279 29121 3399 91% 
4868 B06 21710 277 41637.8 3275 91% 
4868 C06 22801 280 23746.6 3411.9 91% 
4868 D06 22806 262 22800.8 3340.4 93% 
4868 E06 22881 266 24451 2669.7 91% 
4868 F06 25678 277 29447 3737.5 92% 
4868 G06 25740 298 26944.3 3108.9 91% 
4868 H06 26692 296 30437.9 7544.7 91% 
4868 A07 28377 269 23468.4 3432.8 93% 
4868 B07 29073 276 21531.3 3252.7 92% 
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4868 C07 30813 272 20785.6 3563.4 93% 
4868 D07 30930 267 22704.1 4622.8 91% 
4868 E07 31069 297 21848.9 3310.5 90% 
4868 F07 31698 265 30911.8 6889.8 92% 
4868 G07 31703 295 79418.3 3523.3 86% 
4868 H07 33010 253 35941.4 3393.8 87% 
4868 A08 34875 272 28994 3354.9 91% 
4868 B08 34879 267 28025.1 3401.1 92% 
4868 C08 34910 291 44710.6 3466.3 87% 
4868 D08 36586 270 30650.4 3328.7 89% 
4868 E08 36753 274 24236.6 3047.5 91% 
4868 F08 36815 264 33174.6 3000.4 91% 
4868 G08 37612 269 46333.3 9976 91% 
4868 H08 37955 261 38882.4 4728.8 89% 
4868 A09 38352 295 24026.5 3573.7 93% 
4868 B09 39047 256 22394.6 3323.2 91% 
4868 C09 39938 281 26350.2 6264.7 91% 
4868 D09 40275 263 24319.9 3364.5 91% 
4868 E09 40306 298 30544.8 3341.4 90% 
4868 F09 41066 286 27235.2 3015.1 91% 
4868 G09 41376 278 27749.6 2950.1 91% 
4868 H09 41378 277 28814.6 2973.3 91% 
4868 A10 41649 260 29504.5 3166.5 91% 
4868 B10 41805 300 23932.6 3224.2 92% 
4868 C10 42096 294 23056.3 2978.7 93% 
4868 D10 42135 280 23452.2 3808.5 92% 
4868 E10 43308 288 55065.1 3194.7 73% 
4868 F10 43344 300 29234.5 2895.9 91% 
4868 G10 44556 287 26574 2951.6 90% 
4868 H10 45086 261 44399.6 2995.7 91% 
4868 A11 45536 266 13826.5 2167.1 81% 
4868 B11 45745 261 22678.2 2847.7 92% 
4868 C11 46212 298 20977.6 2853.5 80% 
4868 D11 47522 255 31265.2 3454.4 91% 
4868 E11 49643 292 25203.9 2839 91% 
4868 F11 49847 274 27197.2 2881.7 91% 
4868 G11 50199 260 120586.4 64337.9 89% 
4868 H11 51349 283 46718.4 3065.5 90% 
4869 A02 51351 284 105235.6 1585.6 49% 
4869 B02 52241 284 50834.6 1895.3 91% 
4869 C02 55172 285 26449.1 1986.6 92% 
4869 D02 55453 272 33817.3 2001.1 91% 
4869 E02 55845 285 33166.5 2039.6 92% 
 84 
4869 F02 55862 298 28609.1 2919.6 93% 
4869 G02 58347 281 29488.1 2232.5 91% 
4869 H02 58724 256 28202.2 2449 92% 
4869 A03 59430 284 24729.1 2047.8 92% 
4869 B03 59782 252 25414.9 1958 92% 
4869 C03 59984 265 42740.6 2915.1 91% 
4869 D03 60303 278 31815.4 3199.9 91% 
4869 E03 61929 294 27737 2020.3 91% 
4869 F03 62901 259 27006.9 1983 92% 
4869 G03 63161 264 27353.3 2163 92% 
4869 H03 66020 259 27916.7 2014.8 91% 
4869 A04 68841 267 29063.2 2066.6 92% 
4869 B04 68971 273 25836.1 2017.5 92% 
4869 C04 70307 267 24366.6 1961.8 90% 
4869 D04 72947 282 30012.5 1977.1 92% 
4869 E04 73295 252 25721.5 1992.8 92% 
4869 F04 73753 289 28806.6 2032.9 92% 
4869 G04 76549 261 25499.8 2059.8 92% 
4869 H04 76747 272 111768.8 106674 90% 
4869 A05 78623 292 24749.5 2067 91% 
4869 B05 78697 264 21726.6 2527.2 88% 
4869 C05 82269 272 27370.9 3070.3 92% 
4869 D05 87008 293 26020.9 1986.8 92% 
4869 E05 87690 271 25136.1 1997.6 90% 
4869 F05 88324 251 23614.3 2015 91% 
4869 G05 88349 254 26679.3 1967.1 91% 
4869 H05 88402 292 31919.8 2504.2 90% 
4869 A06 88795 253 30062.2 2080.3 92% 
4869 B06 89349 284 23057.5 2330.1 92% 
4869 C06 89429 296 29576.6 1984.5 93% 
4869 D06 89759 258 26248.6 1929.4 93% 
4869 E06 92849 278 24461 1947.6 93% 
4869 F06 93427 286 8841.9 1413.1 90% 
4869 G06 93945 262 21994.3 1786.8 92% 
4869 H06 95909 266 25223.1 1855.4 91% 
4869 A07 97865 277 24524.8 1943.6 91% 
4869 B07 98026 300 27507 1990 91% 
4869 C07 98049 262 55043.2 2022.1 93% 
4869 D07 98938 280 65154.8 5947.3 90% 
4869 E07 100058 287 22969.7 2037 92% 
4869 F07 100942 274 24167 1922 92% 
4869 G07 101298 269 18993.6 2006.3 82% 
4869 H07 101345 265 31189.5 1967.3 91% 
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4869 A08 101679 273 23885.4 1980.9 92% 
4869 B08 101758 259 22936.6 1963.6 93% 
4869 C08 102554 263 23977.5 1974.7 92% 
4869 D08 103189 299 24743.4 1999.8 92% 
4869 E08 105432 284 24083.5 1944.3 93% 
4869 F08 108783 272 37344.6 2015.6 92% 
4869 G08 109747 263 38074.1 10457 91% 
4869 H08 111847 263 55884.3 8642.1 88% 
4869 A09 17055 280 434677 390321.4 91% 
4869 B09 20618 258 34940.5 13892.7 91% 
4869 C09 20619 258 27358.7 4164.8 90% 
4869 D09 23715 265 28886.3 2775 92% 
4869 E09 32892 278 25939.1 2534.5 92% 
4869 F09 40749 290 26604.5 1644.9 91% 
4869 G09 43409 266 26305.9 2164.4 91% 
4869 H09 50680 293 80936.5 6639.3 92% 
4869 A10 54645 283 29598.6 2800.2 91% 
4869 B10 54860 289 45893.9 3384 82% 
4869 C10 79887 298 66068.4 2447.4 89% 
4869 D10 107022 278 24659.3 2787.8 92% 
4869 E10 33173 269 121065.7 102757.2 89% 
4869 F10 38007 256 28277.7 8874 86% 
4869 G10 60037 286 19303.9 1475.4 89% 
4869 H10 66122 284 18016.4 2099.2 90% 
4869 A11 14311 263 22185.5 2357.5 92% 
4869 B11 21970 268 29951.3 13298.7 90% 
4869 C11 33182 276 22834.1 2923.2 91% 
4869 D11 45815 264 23094 2233 91% 
4869 E11 53934 295 24950.8 2327.4 92% 
4869 F11 76478 287 86441.8 2258.4 87% 
4869 G11 92937 261 53571.9 36517 80% 
4869 H11 110899 254 26667.4 4444.2 91% 
4870 A02 112541 292 77769 2046.4 92% 
4870 B02 112547 298 58009 2771.3 91% 
4870 C02 112965 271 58816.6 2355.5 93% 
4870 D02 116640 295 66203.9 6237.7 94% 
4870 E02 116644 270 154186.4 120376.9 93% 
4870 F02 117197 299 75389.7 12206.8 92% 
4870 G02 117446 261 65697.9 6168.3 92% 
4870 H02 117908 286 67758.5 5583.2 93% 
4870 A03 118628 288 59604 3823.9 91% 
4870 B03 119805 295 55381.4 3042.5 92% 
4870 C03 120631 258 55727.1 2818.2 92% 
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4870 D03 120913 262 60256.3 2648.8 93% 
4870 E03 120961 280 61946.2 2595.6 93% 
4870 F03 121268 272 63111.9 2533.1 92% 
4870 G03 122253 290 63686.6 2474.6 93% 
4870 H03 125344 281 64625 2499.6 92% 
4870 A04 125605 257 41756.7 2114.9 90% 
4870 B04 126224 265 104065.8 2401 89% 
4870 C04 127886 278 56751.1 2374.9 92% 
4870 D04 129220 285 54884.8 2336.6 92% 
4870 E04 129929 266 275645.9 244496.5 91% 
4870 F04 130801 280 76635.9 21178.3 94% 
4870 G04 130847 289 138334.4 6821.8 92% 
4870 H04 133002 259 62643.1 4055.5 91% 
4870 A05 133351 290 52907.4 3306.8 92% 
4870 B05 134058 251 56314.1 3017.5 93% 
4870 C05 134199 294 53508.3 3040.4 92% 
4870 D05 134674 257 57954.5 2835.1 93% 
4870 E05 135412 288 60664.8 2843.9 92% 
4870 F05 135894 269 58415.7 2738.9 87% 
4870 G05 137399 273 63542.1 2711.3 90% 
4870 H05 137577 275 79689.8 2646.1 93% 
4870 A06 138389 253 150212.9 2857 89% 
4870 B06 138398 289 54385.8 3244.1 92% 
4870 C06 139021 255 56109.5 3727.4 90% 
4870 D06 140873 277 58413.5 2774.5 92% 
4870 E06 140899 268 59519.9 2767.8 92% 
4870 F06 141538 296 79725 2687.6 92% 
4870 G06 142269 273 58509.4 2599.4 92% 
4870 H06 144694 274 65965.2 2703.6 90% 
4870 A07 147866 282 55340.3 2760.9 92% 
4870 B07 148832 264 52247.1 2612.8 92% 
4870 C07 151262 285 57940.4 3285 91% 
4870 D07 153172 272 53320.5 2464.5 93% 
4870 E07 153792 269 56877.6 2658.4 92% 
4870 F07 154127 281 122103.7 2689.8 90% 
4870 G07 156957 263 59276.5 2622.4 92% 
4870 H07 157522 275 60667.1 2678.9 92% 
4870 A08 158549 260 183810.3 20023.6 92% 
4870 B08 159686 257 65079.4 4985.1 93% 
4870 C08 162188 275 57250.1 3381.4 92% 
4870 D08 163802 258 54630.3 3000.2 91% 
4870 E08 164464 275 56810.8 3090.3 92% 
4870 F08 165599 287 57069.9 2893.1 92% 
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4870 G08 165701 295 60212.7 2855.4 91% 
4870 H08 166596 268 78886.5 2937.4 91% 
4870 A09 166634 267 51583.1 2777 90% 
4870 B09 166846 266 49905.3 2819.6 91% 
4870 C09 168221 286 72395.3 3239 91% 
4870 D09 168225 278 52449.9 2890 91% 
4870 E09 170637 256 47748.1 2537.6 92% 
4870 F09 170955 291 55153.9 3024 92% 
4870 G09 174084 295 63160.2 2913.6 90% 
4870 H09 175743 268 59170.7 2734.6 90% 
4870 A10 176367 257 54266.4 2763.9 92% 
4870 B10 177866 259 50829.1 3480 91% 
4870 C10 178873 268 53575.3 2653.8 92% 
4870 D10 179822 260 50091.3 2649.9 92% 
4870 E10 180964 274 57042.1 2832.8 91% 
4870 F10 193528 272 57785.1 2841.8 92% 
4870 G10 195327 271 53657.1 2657.4 89% 
4870 H10 197046 252 58911.6 2632.5 93% 
4870 A11 201634 274 46142.2 3172.2 90% 
4870 B11 203837 267 46641.7 2648.6 91% 
4870 C11 205909 290 52590.8 3856.3 90% 
4870 D11 205913 262 56058.8 4496.9 90% 
4870 E11 207895 279 107272.3 2596.1 87% 
4870 F11 211336 273 58479.3 2550.3 91% 
4870 G11 213708 253 55709.1 2710.6 92% 
4870 H11 214029 265 68725.6 16258.2 87% 
4871 A02 215275 296 24821.1 1581.9 73% 
4871 B02 215585 266 18579.5 1561.4 77% 
4871 C02 216183 289 208936 1376.5 88% 
4871 D02 216618 265 20433.5 1544.4 88% 
4871 E02 236254 266 21567 1518.9 87% 
4871 F02 238929 273 15242.9 1510.9 85% 
4871 G02 240029 280 19049.1 1498.7 89% 
4871 H02 241621 279 27228.7 10248.7 88% 
4871 A03 241998 294 20366.5 1517.3 88% 
4871 B03 242557 282 31208.6 1469.2 89% 
4871 C03 265372 264 18496.9 1491.2 88% 
4871 D03 283856 262 20090.2 1451.8 88% 
4871 E03 285669 254 19954.7 1467.5 88% 
4871 F03 288024 297 18862.8 1455.9 89% 
4871 G03 289748 262 17023.3 1610.3 88% 
4871 H03 294150 291 18540.4 1519.9 87% 
4871 A04 294625 287 16943.8 1519.3 87% 
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4871 B04 294747 271 20333.5 1530.1 88% 
4871 C04 296934 297 19867.4 1485.6 88% 
4871 D04 299514 288 17713.8 1761.6 86% 
4871 E04 299967 287 20791.8 1491.1 87% 
4871 F04 299968 270 20319.7 1808.1 86% 
4871 G04 301167 272 19462.3 1465.6 88% 
4871 H04 302584 278 22306.4 1386.4 88% 
4871 A05 302867 288 16864.6 1569.6 84% 
4871 B05 303304 258 42408.1 1596.1 88% 
4871 C05 305329 262 39333.9 19942.5 85% 
4871 D05 305743 258 38021.3 1809.8 85% 
4871 E05 307703 257 22400.8 1561.9 88% 
4871 F05 308814 283 29509.9 14102.3 83% 
4871 G05 310113 278 19170 2907.3 84% 
4871 H05 311165 285 26042.7 1493.8 88% 
4871 A06 312606 284 35711 8505.1 86% 
4871 B06 316458 263 19188.9 2469.6 88% 
4871 C06 318799 262 18675.9 1838.7 88% 
4871 D06 319029 288 18959.2 1675.4 89% 
4871 E06 319079 297 20766.8 1742.3 88% 
4871 F06 319436 299 20696.8 1637.1 88% 
4871 G06 319471 252 18291.3 1529.8 88% 
4871 H06 321792 254 20270.9 1876.9 89% 
4871 A07 326644 269 30811.3 1641.7 88% 
4871 B07 326921 274 20690.3 1577.1 89% 
4871 C07 327444 268 20492.5 2357 88% 
4871 D07 328130 261 19030.3 1572.1 86% 
4871 E07 331972 263 37895.6 1479.5 88% 
4871 F07 332452 286 18454.8 1523.6 88% 
4871 G07 338564 277 17835.5 1575.4 86% 
4871 H07 343526 265 30864.7 1684.8 87% 
4871 A08 343557 281 27698.3 8019.7 87% 
4871 B08 348970 258 33603.7 12487.7 88% 
4871 C08 351674 286 43191.2 11264.8 89% 
4871 D08 351691 260 21279.7 2090.1 88% 
4871 E08 352888 279 17616.2 1637.6 88% 
4871 F08 358311 271 24376.8 5534.8 77% 
4871 G08 361570 283 15688 1679.1 84% 
4871 H08 364889 299 18113.7 2049.6 88% 
4871 A09 366086 269 19731.4 1702.9 85% 
4871 B09 366802 298 20445.1 1629.1 87% 
4871 C09 367474 281 18400.1 1609.2 88% 
4871 D09 367480 298 18188.1 1603.1 86% 
 89 
4871 E09 369066 269 20730.1 1470.6 88% 
4871 F09 369070 299 18115.1 1333.5 86% 
4871 G09 122385 270 16950.1 1543.8 87% 
4871 H09 164880 291 49016.1 2940 89% 
4871 A10 228155 290 64793 7697.5 64% 
4871 B10 294153 288 22312.2 1793 85% 
4871 C10 362093 275 38264.2 1628.1 86% 
4871 D10 363801 253 20721.2 1581.7 88% 
4871 E10 367416 282 19268.6 5134.6 75% 
4871 F10 217306 290 17278.9 2121.2 87% 
4871 G10 276736 281 22638.9 1906.6 87% 
4871 H10 283845 273 62005.4 1711.4 84% 
4871 A11 116508 276 18518.6 1676.5 86% 
4871 B11 149312 266 18704 1679.7 85% 
4871 C11 204939 295 49529.8 1749.2 86% 
4871 D11 252172 278 17658.6 1669.8 79% 
4871 E11 269904 299 20709.9 1720 87% 
4871 F11 280492 298 17742.1 1571.8 79% 
4871 G11 330796 283 18364.1 2161.2 84% 
4871 H11 331977 254 20742.8 1572.3 86% 
4872 A02 370383 264 17867.9 2119.1 86% 
4872 B02 372769 290 72623.4 2148.9 84% 
4872 C02 373981 257 17313.6 2645.9 86% 
4872 D02 374703 298 34370.3 2058 87% 
4872 E02 374814 276 21505.6 2174.1 86% 
4872 F02 375105 285 2515879 2676081 83% 
4872 G02 378711 281 61466.9 44635.6 87% 
4872 H02 379468 296 39290.6 22363.9 84% 
4872 A03 379536 296 28953.9 12195.3 86% 
4872 B03 379651 277 32929.6 10556.4 85% 
4872 C03 380279 295 24059.6 7442.4 87% 
4872 D03 400770 274 23382.6 7329.6 78% 
4872 E03 400938 253 41459.7 4802.1 85% 
4872 F03 403268 265 22046.6 5023.3 85% 
4872 G03 408734 273 21171.1 4569 86% 
4872 H03 408860 286 21712.6 4063.4 87% 
4872 A04 522131 297 33494.8 6193.7 85% 
4872 B04 524615 278 20499.4 3864.6 87% 
4872 C04 525721 271 21470.7 3488.4 86% 
4872 D04 636718 264 35887.4 3434 84% 
4872 E04 637343 276 16201.4 9963.6 82% 
4872 F04 637359 258 27370.6 4676.2 86% 
4872 G04 637827 276 31553.8 4116.1 79% 
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4872 H04 638636 257 23291.1 3434.1 84% 
4872 A05 641396 291 27100.6 22433.1 71% 
4872 B05 643029 280 24385.7 5594.6 69% 
4872 C05 645330 275 58961.8 62570.2 81% 
4872 D05 661221 275 22474.7 30113.3 76% 
4872 E05 680515 265 8303.4 1787.1 57% 
4872 F05 689002 287 16878.4 3370.9 77% 
4872 G05 3753 304 21746.4 3574.8 86% 
4872 H05 5053 335 19269.9 2966.8 86% 
4872 A06 5476 334 30219.1 3326.6 85% 
4872 B06 6101 330 21399.4 2887.3 73% 
4872 C06 7436 304 21449.7 2978.4 84% 
4872 D06 7578 343 26219.7 2788.6 87% 
4872 E06 9037 336 16544 2388.1 85% 
4872 F06 11437 302 7708.7 1915.8 51% 
4872 G06 12262 314 30966.1 2681.6 86% 
4872 H06 12544 320 19698.2 2664.5 87% 
4872 A07 12628 321 18904.4 2580.7 85% 
4872 B07 12650 322 18527.2 2522 86% 
4872 C07 13156 314 22482.4 5439.8 86% 
4872 D07 13176 318 46733 2762.8 79% 
4872 E07 13616 327 125306.2 9156.5 86% 
4872 F07 14142 327 20478.2 2837.2 86% 
4872 G07 14506 332 25981.8 2724.9 85% 
4872 H07 16722 302 19966.7 2495.4 86% 
4872 A08 17128 348 25037.1 2505.9 86% 
4872 B08 18883 349 381837 18006 71% 
4872 C08 24032 310 45071 35012.4 79% 
4872 D08 24951 350 18413.5 2720.5 86% 
4872 E08 25435 310 40082.4 2700.5 87% 
4872 F08 25457 348 840205.3 847977.7 55% 
4872 G08 26349 302 23936.6 6438.5 85% 
4872 H08 26980 334 20258.5 3894.9 85% 
4872 A09 27305 324 19590.4 3277.7 86% 
4872 B09 28080 312 55557 19860.5 71% 
4872 C09 30205 314 38236.5 12353 71% 
4872 D09 30260 349 17245.8 2242.4 86% 
4872 E09 32673 334 20514.8 2288.9 75% 
4872 F09 32873 305 17234.2 2287.5 86% 
4872 G09 33353 337 30968.3 6062.5 33% 
4872 H09 33478 328 18409.6 2288.3 84% 
4872 A10 33738 339 26274.9 2377.7 86% 
4872 B10 34219 313 20618.6 2286.1 80% 
 91 
4872 C10 34865 322 17569.3 2269.2 86% 
4872 D10 35582 347 18324.9 2268.8 73% 
4872 E10 36693 332 32206.3 2409.2 86% 
4872 F10 36758 305 17491.3 3116.7 72% 
4872 G10 36923 317 26307.4 2235 85% 
4872 H10 37168 308 16229.4 1919.9 84% 
4872 A11 37187 312 23663.9 5744 81% 
4872 B11 38090 333 57150.5 2203.9 85% 
4872 C11 39984 314 22336.8 4907.6 85% 
4872 D11 40269 326 19051.2 2298.9 87% 
4872 E11 41098 312 11469.1 1373.5 79% 
4872 F11 43088 335 13089.9 1861 86% 
4872 G11 43506 315 16851.8 2226.3 85% 
4872 H11 44584 334 19553.7 2047.7 82% 
4873 A02 44750 312 13034.9 2148.6 90% 
4873 B02 45527 304 8881.7 1662.6 90% 
4873 C02 46213 312 13983.2 1885.8 37% 
4873 D02 46492 313 486339.2 2203.4 65% 
4873 E02 48388 330 25045.5 2027.1 91% 
4873 F02 50648 308 31237.2 1852.1 84% 
4873 G02 50651 336 118219.3 9314.5 80% 
4873 H02 50690 307 27259.6 4373.7 89% 
4873 A03 51683 315 12778.2 2355.4 91% 
4873 B03 55152 346 13536 2061.2 50% 
4873 C03 59814 317 13701.1 2060.5 92% 
4873 D03 60013 307 16623.3 1952.4 56% 
4873 E03 60183 310 34636.2 2084.6 91% 
4873 F03 60423 321 38980.6 2608.7 89% 
4873 G03 61642 344 26236.6 2283 88% 
4873 H03 62375 310 26724.3 2137.5 91% 
4873 A04 64672 344 12703.1 2014.1 90% 
4873 B04 65689 327 16591.1 3670.9 90% 
4873 C04 68116 315 15322.4 2106.7 90% 
4873 D04 69359 302 20803.3 2055.2 90% 
4873 E04 70413 327 22501.8 2044.8 90% 
4873 F04 71097 310 42280.3 8109.3 84% 
4873 G04 71866 305 21888.3 2111.6 90% 
4873 H04 71881 314 24974.2 2214 77% 
4873 A05 76988 302 13085.3 2445.8 91% 
4873 B05 79486 340 299710.5 2208.3 88% 
4873 C05 79559 308 11294.2 2162.8 74% 
4873 D05 81750 329 16314.3 2108.9 90% 
4873 E05 82560 309 20296.6 2023.4 58% 
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4873 F05 83497 326 23973 1992.3 88% 
4873 G05 86467 328 38563.6 2186 89% 
4873 H05 87084 331 26274.8 2230.6 90% 
4873 A06 87136 312 14918 2013.8 90% 
4873 B06 87838 346 15052.6 2805.3 89% 
4873 C06 90749 303 23697.4 5894.3 91% 
4873 D06 91378 342 21136 2121.4 90% 
4873 E06 91382 340 65535.5 2165.6 88% 
4873 F06 92892 337 24006.6 2042.8 89% 
4873 G06 93033 305 24046.7 2264.4 89% 
4873 H06 95204 306 26899.6 2172.4 90% 
4873 A07 95916 343 21703.2 9810 91% 
4873 B07 653004 291 14588.8 3399.1 90% 
4873 C07 1014 341 8845.8 2784.4 87% 
4873 D07 22070 306 27953.1 2390 92% 
4873 E07 26112 306 13393.6 2142.5 78% 
4873 F07 33570 321 76886.2 2187 88% 
4873 G07 36525 342 39587.5 2252.6 91% 
4873 H07 43271 304 22335.6 2152.8 73% 
4873 A08 53874 327 12162.3 2047.5 89% 
4873 B08 56779 304 11805.6 2153.1 90% 
4873 C08 87010 302 13463.2 2164.4 91% 
4873 D08 636734 279 15065.4 2098.8 86% 
4873 E08 6268 318 18263 1977.2 82% 
4873 F08 11307 314 30388.7 2128.8 88% 
4873 G08 26113 318 11714.6 2605.2 81% 
4873 H08 35545 301 25125.3 2193.2 89% 
4873 A09 43998 318 43675.7 39009.2 85% 
4873 B09 47680 301 13874.6 3534.1 89% 
4873 C09 48443 332 57019.6 27230.6 79% 
4873 D09 66695 340 15122.6 2332 88% 
4873 E09 73254 347 22746.8 2298.1 88% 
4873 F09 80313 325 30849.6 2257.7 88% 
4873 G09 94600 348 34403.6 7157.4 85% 
4873 H09 524385 268 34397.1 2472.4 88% 
4873 A10 680516 290 148797.9 1491.6 87% 
4873 B10 30622 333 11039 2048.3 90% 
4873 C10 19123 305 12603.8 2829.7 62% 
4873 D10 3064 328 21152.7 3732.3 88% 
4873 E10 33575 345 10480.3 1787.6 89% 
4873 F10 45545 308 23011.3 2738.4 81% 
4873 G10 48617 312 61485.4 2384.4 89% 
4873 H10 60659 312 34862.6 2493.9 87% 
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4873 A11 63543 326 17179.7 2193 86% 
4873 B11 64859 328 19149.2 2186.1 87% 
4873 C11 70895 316 15560.1 2251.9 87% 
4873 D11 76015 344 15784 2179.1 87% 
4873 E11 81493 303 20812.6 2216.7 87% 
4873 F11 81856 327 25890.7 2021.6 85% 
4873 G11 83961 303 53035.8 2290 87% 
4873 H11 25673 347 30092.9 2368.9 86% 
4874 A02 96541 310 18282.4 2747.3 93% 
4874 B02 96996 339 24736.6 2077.9 92% 
4874 C02 99634 322 16764.8 1768.1 93% 
4874 D02 99660 339 20383.4 1968.6 93% 
4874 E02 99663 319 20131.5 1791.8 92% 
4874 F02 101789 311 18862.7 1647 85% 
4874 G02 105348 330 14058.3 1748 71% 
4874 H02 105781 304 217366 3894.7 91% 
4874 A03 105798 328 37608.4 24039.8 94% 
4874 B03 105827 325 25710.3 9102.8 88% 
4874 C03 106464 332 21635.7 6068.9 94% 
4874 D03 110332 303 20418.3 5251 93% 
4874 E03 110562 302 19418.2 4284 93% 
4874 F03 111194 347 16465.4 3731.8 91% 
4874 G03 112203 311 18413.9 4182.9 92% 
4874 H03 114449 338 17672.1 3818.6 85% 
4874 A04 114997 326 21216 3209.4 93% 
4874 B04 116397 329 18546.3 2939.5 93% 
4874 C04 120290 332 17916.1 2661.1 88% 
4874 D04 120622 316 16681.3 2501.5 89% 
4874 E04 121908 306 16756.2 2421.6 88% 
4874 F04 123389 325 107561.2 89006.8 91% 
4874 G04 126226 302 32410.1 15577.9 92% 
4874 H04 126347 328 30047.2 3742.5 92% 
4874 A05 129536 310 20654.8 3730.9 93% 
4874 B05 133114 346 20709.6 3034.3 79% 
4874 C05 135184 308 19438.9 2745.4 93% 
4874 D05 137112 347 19438.4 2552.1 91% 
4874 E05 142277 320 16785.6 2317.8 91% 
4874 F05 143974 336 20428.9 2446.1 92% 
4874 G05 146071 320 21223.6 2095.8 68% 
4874 H05 146554 350 22834.2 3666.4 92% 
4874 A06 146769 334 15099.6 1970.8 87% 
4874 B06 146770 304 16807.4 2086.9 91% 
4874 C06 147358 301 151557.6 2592.6 90% 
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4874 D06 149054 307 17488.2 2057.7 93% 
4874 E06 153391 328 17310.2 2082.3 91% 
4874 F06 154585 335 16963 2013.9 91% 
4874 G06 157725 329 16636.6 1987.4 93% 
4874 H06 158959 316 27423.8 3590.3 73% 
4874 A07 159092 332 17281.7 2088.1 85% 
4874 B07 159398 347 19510.7 1964.1 92% 
4874 C07 164435 338 17833.6 2109.3 93% 
4874 D07 164459 305 17854.4 2044.9 92% 
4874 E07 165704 336 17552.5 2041.7 91% 
4874 F07 169409 339 23238.8 2002.5 92% 
4874 G07 176736 335 62722.2 1834.7 80% 
4874 H07 177407 333 53720.7 3514.2 91% 
4874 A08 186067 339 20298.1 2711.1 92% 
4874 B08 186194 324 20402 2045.8 92% 
4874 C08 186200 340 35944.4 2042.5 90% 
4874 D08 190501 326 36310.8 2050.7 88% 
4874 E08 191441 347 16481.2 1926.1 92% 
4874 F08 194308 306 26002.9 2187 91% 
4874 G08 201659 323 17482.6 2307.2 90% 
4874 H08 201989 343 18667.8 3438.1 91% 
4874 A09 202705 305 287410.8 104150.3 91% 
4874 B09 205827 301 36839.1 22853.6 82% 
4874 C09 205832 350 35787.6 18459.3 50% 
4874 D09 205842 319 21929.8 6529.9 92% 
4874 E09 205912 325 19734.9 5195.2 91% 
4874 F09 211340 303 20683.9 4389 91% 
4874 G09 211787 326 32586.8 3661.3 93% 
4874 H09 215684 318 21517.3 3361.9 92% 
4874 A10 215689 345 18463.5 3083.3 92% 
4874 B10 216607 320 25330.1 3087.8 91% 
4874 C10 216621 350 29739.3 3097.6 90% 
4874 D10 216623 301 18310.3 2802.4 84% 
4874 E10 228137 334 16414 2284 89% 
4874 F10 228150 303 18501.9 8932.3 84% 
4874 G10 241619 305 23096.6 2383.8 92% 
4874 H10 241624 332 78058.5 3285.8 92% 
4874 A11 244387 328 20199.6 2272 91% 
4874 B11 246999 331 19365.9 2340.9 67% 
4874 C11 270063 308 22015.6 4898.9 90% 
4874 D11 270916 337 40144.8 2458.4 91% 
4874 E11 281307 331 18132.6 2144.7 91% 
4874 F11 281383 319 18583.4 2074.4 92% 
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4874 G11 281623 340 15795.5 2875.7 84% 
4874 H11 281624 310 16883.4 3209.7 89% 
4875 A02 282137 314 23366.8 2308.6 92% 
4875 B02 283849 328 36016.5 2281.5 93% 
4875 C02 288387 348 28733.1 6203.2 94% 
4875 D02 293360 343 55927.9 2005.2 93% 
4875 E02 294750 310 22607.2 2221 92% 
4875 F02 294756 333 43394.9 2003.9 92% 
4875 G02 295300 330 39635.9 2360.4 95% 
4875 H02 299119 312 19785.9 1897.5 92% 
4875 A03 300540 331 22037.5 2469.2 91% 
4875 B03 303294 347 28754.3 2121 93% 
4875 C03 303612 322 230718 2317.1 68% 
4875 D03 305780 341 205108.1 7592.6 4% 
4875 E03 308848 311 22072.9 4041.4 88% 
4875 F03 308849 309 24890 3108.6 75% 
4875 G03 319012 321 30977 2070.3 93% 
4875 H03 319424 309 25138.4 2030.1 93% 
4875 A04 319449 341 31144.6 11195.8 93% 
4875 B04 321517 313 41222.1 2380.6 93% 
4875 C04 326182 309 30147.4 2250.7 91% 
4875 D04 326385 334 23414.6 2201.9 93% 
4875 E04 326422 306 19788.1 2053.9 92% 
4875 F04 326757 318 20206.6 1975 88% 
4875 G04 328010 336 32523.8 2067.7 95% 
4875 H04 328111 325 131863.4 106392.4 94% 
4875 A05 329052 322 23274.5 2398 93% 
4875 B05 329255 329 25398.1 2365.5 82% 
4875 C05 330770 311 346925.6 323595.4 67% 
4875 D05 332670 310 153482.6 96031.5 93% 
4875 E05 333544 336 39406 17596.8 92% 
4875 F05 335504 337 34893.6 11345.2 92% 
4875 G05 339589 322 57811.9 9690.3 94% 
4875 H05 339594 339 51710.9 6702.2 93% 
4875 A06 339630 339 31293.4 7189.3 92% 
4875 B06 341956 307 34541.4 6218.8 95% 
4875 C06 343550 309 36134.8 5895.8 93% 
4875 D06 345850 332 25006.4 5624.8 93% 
4875 E06 346578 339 112780 49034.2 91% 
4875 F06 349156 325 28323.8 10573.8 89% 
4875 G06 352890 302 25765.8 7256 92% 
4875 H06 362639 344 25350.3 6442.6 91% 
4875 A07 366289 303 46590.1 15755.1 89% 
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4875 B07 366801 333 23842.3 5712 90% 
4875 C07 369986 329 26132.7 6378.3 91% 
4875 D07 371765 318 113425.6 5551.1 94% 
4875 E07 372146 305 46317.9 4521.8 91% 
4875 F07 372275 322 20720 4314.5 78% 
4875 G07 372287 339 34499.9 3922.4 93% 
4875 H07 135381 304 23634.8 3894.9 91% 
4875 A08 145992 301 27640.1 4169.7 91% 
4875 B08 187675 323 29542.7 3938.9 91% 
4875 C08 201868 318 23095.5 4374.3 84% 
4875 D08 209901 331 17920.2 3421.9 87% 
4875 E08 217913 307 26046.3 4122.8 91% 
4875 F08 326184 316 32743 3406.6 81% 
4875 G08 329249 348 35313.5 3251.2 90% 
4875 H08 337726 304 26169.8 3706.1 92% 
4875 A09 343549 301 54451.3 3308.9 92% 
4875 B09 211356 346 24307.6 3208.8 90% 
4875 C09 222362 319 23674.7 3174.3 90% 
4875 D09 252359 342 45442.3 3664 90% 
4875 E09 300289 339 49955 2788.8 73% 
4875 F09 321502 346 18446.7 2779.5 92% 
4875 G09 324623 327 37296.2 16075.8 92% 
4875 H09 98363 342 37173.3 3975.9 87% 
4875 A10 99657 325 28017 4784.6 92% 
4875 B10 111118 331 27353.2 2940 91% 
4875 C10 112125 312 41059.1 3369.1 92% 
4875 D10 133075 343 21438.6 3019.8 93% 
4875 E10 135168 313 18910.2 2854 94% 
4875 F10 142446 349 21838.6 3965.6 60% 
4875 G10 150114 303 40335.4 2702.3 92% 
4875 H10 156563 350 17929.3 3046.9 91% 
4875 A11 197008 336 26300.4 2890.3 92% 
4875 B11 245091 324 24333.8 2848.2 92% 
4875 C11 278323 326 22415.9 2763.4 93% 
4875 D11 326375 338 30695.8 2618.7 92% 
4875 E11 329250 349 20633.3 2509.5 79% 
4875 F11 331968 301 18485.3 2644.4 90% 
4875 G11 338578 318 21147.3 2533.8 87% 
4875 H11 339316 303 14781.4 2000.4 93% 
4876 A02 372499 308 51341.4 10573.9 91% 
4876 B02 375981 337 27448.8 3030.8 91% 
4876 C02 375982 344 28611.7 2784.5 90% 
4876 D02 378717 333 110878.9 39048.8 87% 
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4876 E02 379538 304 32858.2 7243.3 89% 
4876 F02 379697 343 44115.6 2916 92% 
4876 G02 401077 334 23587.1 3041.5 91% 
4876 H02 403447 304 35955.7 2979.7 91% 
4876 A03 623109 307 29144.3 2602.5 92% 
4876 B03 623638 350 38656.3 3373.3 91% 
4876 C03 631160 317 40762.8 2276.6 91% 
4876 D03 632536 323 39450.7 2133 90% 
4876 E03 637153 327 85413 2468.9 89% 
4876 F03 637317 344 73199 2903 90% 
4876 G03 637325 310 44794.8 3274.2 91% 
4876 H03 651084 347 20516.7 2180.1 91% 
4876 A04 660151 304 46999.9 5699.4 90% 
4876 B04 3323 375 17473.4 1947.7 79% 
4876 C04 5157 395 51746.9 2168.1 91% 
4876 D04 5836 362 26017.6 2214 91% 
4876 E04 7419 393 69201.5 2257 90% 
4876 F04 11668 385 29811.7 3329.8 27% 
4876 G04 12666 364 22836.9 2191.5 90% 
4876 H04 13487 379 895945.9 860556.3 68% 
4876 A05 14974 396 28654.4 3322.1 90% 
4876 B05 16437 368 23057.8 2653.1 87% 
4876 C05 16736 362 32057.3 2377.8 91% 
4876 D05 17355 357 55586.1 2848.1 91% 
4876 E05 19061 385 35004.1 11511.8 84% 
4876 F05 20192 386 225175.8 2561.5 86% 
4876 G05 24113 369 354566.6 19446.3 50% 
4876 H05 29200 357 12992.2 2966.7 73% 
4876 A06 31748 358 27302.1 2554.8 89% 
4876 B06 34871 364 27193.4 2368.1 90% 
4876 C06 36317 384 26744.2 2231.4 90% 
4876 D06 36818 374 25862.6 2206.2 90% 
4876 E06 46075 370 29154 3623.7 87% 
4876 F06 46385 39 24557.6 2262.9 92% 
4876 G06 49852 384 23355.1 2127.5 90% 
4876 H06 50650 363 26196 10295.1 79% 
4876 A07 50654 382 29878.1 12176.4 70% 
4876 B07 50688 358 194231.8 6901.6 91% 
4876 C07 57624 384 22008.3 2736.5 89% 
4876 D07 65537 356 29658.1 1983.6 89% 
4876 E07 70799 377 35967 2083.8 90% 
4876 F07 73053 381 80712.3 19595.3 89% 
4876 G07 76350 398 21306.8 2316.3 90% 
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4876 H07 78846 359 21599.1 2385.8 90% 
4876 A08 80137 386 37107.5 4832.7 89% 
4876 B08 81463 400 28886.4 3657.2 90% 
4876 C08 81915 378 27280 2520.4 91% 
4876 D08 84100 392 18944.1 2240.6 83% 
4876 E08 89602 377 25776.4 2233.1 86% 
4876 F08 91340 381 96052.8 2420.6 69% 
4876 G08 91355 361 122952.3 2408.8 89% 
4876 H08 91356 361 108461.5 2272.3 87% 
4876 A09 91357 361 153760.6 2453.7 81% 
4876 B09 91368 377 69436.2 2387 87% 
4876 C09 91396 397 53243.8 2283.8 46% 
4876 D09 91397 397 19854.5 2141.7 83% 
4876 E09 97920 393 93101.2 51648.6 84% 
4876 F09 99867 363 71168.5 2736.9 83% 
4876 G09 99925 383 15037.3 2150.7 89% 
4876 H09 100708 385 66845.8 2304.5 87% 
4876 A10 103331 399 84556.5 32419.8 82% 
4876 B10 106231 360 42240.3 9322.8 89% 
4876 C10 107679 380 32032 4488.3 87% 
4876 D10 110300 358 25453.4 2993.8 72% 
4876 E10 111210 397 34530 3512.2 41% 
4876 F10 114414 357 14808.9 2149.7 82% 
4876 G10 117268 379 20027.1 2481 89% 
4876 H10 117987 360 28606.5 2153.1 89% 
4876 A11 118818 369 58711 2512.9 90% 
4876 B11 124818 354 22547.4 2904.8 88% 
4876 C11 126837 391 33571.1 2282.8 89% 
4876 D11 131467 386 31967.1 6445.7 88% 
4876 E11 131616 354 37554.8 5551.7 89% 
4876 F11 134137 371 23334.4 3400.8 88% 
4876 G11 139168 390 22291.1 2541.8 88% 
4876 H11 151721 354 28536.2 2197.4 90% 
4877 A02 151888 375 3802018.
5 
3758172 77% 
4877 B02 154389 396 36179.5 6093.2 76% 
4877 C02 156565 359 104066.3 1539.9 85% 
4877 D02 159566 351 103172.2 2914.4 85% 
4877 E02 163639 399 40665.5 3216.4 90% 
4877 F02 163823 356 40443.1 2706.5 83% 
4877 G02 164991 367 32460.6 2476.7 58% 
4877 H02 166637 384 142389.5 5053.4 90% 
4877 A03 177862 351 47243.3 2513.9 88% 
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4877 B03 191454 363 36396.9 2607.3 90% 
4877 C03 201863 370 44158.2 2499.2 43% 
4877 D03 204262 396 353245.4 2400.2 89% 
4877 E03 204665 376 63847.4 2306.6 86% 
4877 F03 215721 386 27568.5 2509.2 76% 
4877 G03 216606 354 34475.1 2124.9 77% 
4877 H03 217697 359 69478.5 42034.6 66% 
4877 A04 250429 364 43438.2 3095.8 90% 
4877 B04 263220 388 35570.1 2862.4 90% 
4877 C04 270071 391 37941.6 2502 90% 
4877 D04 271923 359 32344.8 1938.3 91% 
4877 E04 275266 374 38269.8 3424.2 85% 
4877 F04 275971 365 31163.1 2367.7 31% 
4877 G04 289359 352 75436.5 37620.4 83% 
4877 H04 292140 373 40589.4 5291.6 90% 
4877 A05 292923 370 37368.2 4779.9 90% 
4877 B05 293962 366 40004.2 3164.6 90% 
4877 C05 298892 373 71797.1 2592.1 89% 
4877 D05 309401 377 40307.1 12402.5 5% 
4877 E05 310354 372 112120.3 3340.8 46% 
4877 F05 317605 368 205572.7 19973.1 2% 
4877 G05 319435 367 38110.5 4062.1 89% 
4877 H05 319994 362 44703 2504.4 88% 
4877 A06 320218 388 50117.1 2365 87% 
4877 B06 325014 383 40433.9 2524.4 85% 
4877 C06 329065 369 43485.9 2620.9 87% 
4877 D06 338519 355 82736.9 64958.7 86% 
4877 E06 339161 395 37125.4 13191.1 84% 
4877 F06 347463 357 58762.4 5503.6 90% 
4877 G06 630602 347 79652.8 3277.7 79% 
4877 H06 634396 347 27715.7 2943.7 84% 
4877 A07 37219 358 44145.2 3111.5 81% 
4877 B07 56287 365 109489.6 3100.1 83% 
4877 C07 102314 358 62073.6 2772.2 90% 





4877 E07 116709 353 70668.1 9412.7 87% 
4877 F07 120289 390 48199.9 5042.1 86% 
4877 G07 372767 345 31825.4 4388.3 80% 
4877 H07 407628 302 78842.5 22614.9 86% 
4877 A08 32984 369 43295.2 3622.3 90% 
4877 B08 37627 392 39235.5 11331.8 86% 
4877 C08 45572 386 39605.4 2930 88% 
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4877 D08 63680 376 37584.8 2974.2 89% 
4877 E08 117028 398 29063.2 4531.4 75% 
4877 F08 216633 391 37508.6 2674.5 89% 
4877 G08 275428 362 74961.9 4820.1 86% 
4877 H08 295486 359 88018.2 8731.5 87% 
4877 A09 345845 364 45356.5 3615.6 21% 
4877 B09 622608 322 34129.5 3128.6 88% 
4877 C09 622691 317 27735.8 2765.8 81% 
4877 D09 637578 325 56493.9 2888.2 82% 
4877 E09 680495 312 30874.2 2497.3 88% 
4877 F09 4292 380 29143 2553.9 61% 
4877 G09 9032 364 45848.6 3646.4 87% 
4877 H09 11881 390 29975.9 2565.4 87% 
4877 A10 60785 364 35844.5 3006.2 89% 
4877 B10 62685 353 37119.1 2648.2 89% 
4877 C10 84126 385 43508.4 2942.5 88% 
4877 D10 88600 377 39328.8 2583.6 89% 
4877 E10 88916 370 218607.3 2754.1 87% 
4877 F10 125095 375 38691.7 4655.1 81% 
4877 G10 142335 399 94935.1 14500.7 85% 
4877 H10 163443 394 448249.7 335331.2 85% 
4877 A11 178249 354 93769.7 14068.3 83% 
4877 B11 214009 362 26854.5 2602.1 57% 
4877 C11 280594 400 39151.2 5190 88% 
4877 D11 319709 352 41692.5 4426.2 84% 
4877 E11 321491 383 23475 4842.7 82% 
4877 F11 327702 353 23863.6 3008.5 88% 
4877 G11 338042 392 34904 3425 87% 
4877 H11 54709 370 69472.4 3432.6 78% 
4878 A02 350187 388 105505.6 2704.9 91% 
4878 B02 354261 355 73870.3 2643.6 92% 
4878 C02 359472 361 69801.8 2578.8 92% 
4878 D02 367306 381 55685.3 2349.8 91% 
4878 E02 367469 362 30555.4 2404.1 92% 
4878 F02 379388 359 76112.3 2471.2 92% 
4878 G02 379555 358 63974.1 2350.3 92% 
4878 H02 382035 378 182777.6 1569.5 82% 
4878 A03 601359 392 148158.3 26120.9 92% 
4878 B03 603071 363 85262.6 2744.4 77% 
4878 C03 607097 357 63974.8 2300.5 93% 
4878 D03 614826 361 71278.3 2225.2 92% 
4878 E03 622689 353 55935.8 2377.6 90% 
4878 F03 661122 370 625644.8 2313.9 53% 
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4878 G03 665497 368 62548.7 2465.1 92% 
4878 H03 670283 356 48037 2278.1 88% 
4878 A04 672865 367 891522 58723.9 89% 
4878 B04 5856 449 50807.1 10564.3 88% 
4878 C04 12865 405 108444 4570.5 92% 
4878 D04 13294 430 50460.2 5352.4 88% 
4878 E04 13791 447 62316 3044.3 93% 
4878 F04 30625 411 68464.8 2996.5 92% 
4878 G04 41148 414 59911 2762.4 91% 
4878 H04 42199 404 246912.1 2413.9 92% 
4878 A05 53275 434 92047.5 5894.7 90% 
4878 B05 57608 401 85061.1 2554.6 92% 
4878 C05 58904 431 70687.7 2480.6 91% 
4878 D05 65238 408 78456.8 4834.2 7% 
4878 E05 70933 415 71625.5 2509.6 91% 
4878 F05 85433 424 134046.1 2807.5 90% 
4878 G05 89201 440 100772.1 2568 87% 
4878 H05 89821 407 78631.8 3859.4 91% 
4878 A06 105584 422 72395.8 2345.7 91% 
4878 B06 107582 430 81045 1805.4 79% 
4878 C06 107677 409 68175.3 2248.6 91% 
4878 D06 109128 416 182675.4 2312.9 91% 
4878 E06 123418 441 62411.5 2171.4 91% 
4878 F06 123527 412 100735.8 2497.5 91% 
4878 G06 127133 434 71185.8 3768.8 90% 
4878 H06 128606 435 119748 2260.2 91% 
4878 A07 136513 410 69561.2 2332.6 92% 
4878 B07 143241 411 118954.3 9473.1 90% 
4878 C07 164676 404 195263.3 2694.9 90% 
4878 D07 172255 424 184953 2327.3 90% 
4878 E07 201631 436 52420.2 2257.4 78% 
4878 F07 204232 406 50387.9 2203.3 66% 
4878 G07 215718 401 247982.7 1939 70% 
4878 H07 234348 421 79675.7 2197.5 91% 
4878 A08 280058 430 123591.8 2191.2 91% 
4878 B08 290311 421 91434.3 2494.6 91% 
4878 C08 295358 408 60757.3 2210.3 62% 
4878 D08 305798 404 1247659.
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3476.5 1% 
4878 E08 309874 447 78996.8 2383.5 88% 
4878 F08 309892 408 101956.5 43451.6 84% 
4878 G08 321496 411 43388.1 4283.9 89% 
4878 H08 328087 414 87936.3 2745.9 90% 
 102 
4878 A09 328403 427 68581 3583.2 90% 
4878 B09 335506 418 102074.2 4454.5 91% 
4878 C09 337832 430 67196.8 2242.4 91% 
4878 D09 373600 401 66893.9 2229 90% 
4878 E09 376254 447 123952.7 2341.8 90% 
4878 F09 378719 404 101903 6022.6 64% 
4878 G09 379099 402 140818.5 2649.3 46% 
4878 H09 8675 492 3350.2 1991.3 4% 
4878 A10 15910 451 41633.1 2025.4 90% 
4878 B10 19803 464 46253 2058.6 90% 
4878 C10 36508 471 64995.9 2108.9 90% 
4878 D10 37553 477 79294.3 2092.8 83% 
4878 E10 37641 497 187184 2066.5 88% 
4878 F10 41400 493 56971.9 2126.4 91% 
4878 G10 55691 493 41783.3 2029.7 85% 
4878 H10 60339 487 69389.4 4264.1 75% 
4878 A11 64876 495 123085.6 2264.3 89% 
4878 B11 70931 451 94243.4 2318.1 77% 
4878 C11 73735 485 135877.9 3441.9 87% 
4878 D11 80997 473 134326.2 2311.6 77% 
4878 E11 103520 462 61425.4 5692.1 9% 
4878 F11 107522 499 145497.9 2336.7 89% 
4878 G11 116339 459 196242.1 10543.4 1% 
4878 H11 146771 476 59861.6 2125.7 60% 
4879 A02 166375 464 28717 2591.7 90% 
4879 B02 168184 467 26652.1 2794.6 90% 
4879 C02 196515 476 28909.6 2840.4 87% 
4879 D02 211490 472 21599.9 3073.7 87% 
4879 E02 281816 473 1130725 2917.3 56% 
4879 F02 292253 464 33286.5 2682.9 88% 
4879 G02 317003 456 9156.9 747 1% 
4879 H02 319990 475 11061.2 1581.4 80% 
4879 A03 322661 475 93954.9 1886.3 75% 
4879 B03 335979 452 26490.1 2537.6 89% 
4879 C03 342459 469 54207.5 2673.3 89% 
4879 D03 343256 478 262421.4 2784.4 1% 
4879 E03 371178 500 25073 2506.9 90% 
4879 F03 379696 499 46811.1 2471.9 88% 
4879 G03 31762 529 28910.7 2399.3 88% 
4879 H03 45384 521 18985.9 1897.5 81% 
4879 A04 80731 508 15857.9 2311.8 87% 
4879 B04 80735 529 47157 2290.4 86% 
4879 C04 91529 516 25284.8 2668 89% 
 103 
4879 D04 133071 512 27021.3 2652 90% 
4879 E04 139105 539 25681 2560.7 90% 
4879 F04 202386 521 14871 2347.4 26% 
4879 G04 345647 547 113134 63904.6 39% 





4879 A05 654260 550 54767.6 33323.5 86% 
4879 B05 679525 533 26931.8 8626.8 83% 
4879 C05 727038 542 27465.6 5193.8 86% 
4879 D05 143491 579 21562.2 2794.9 81% 
4879 E05 177365 566 23040.9 2793.2 58% 
4879 F05 268251 576 15000.5 2699.3 80% 
4879 G05 330500 561 39483.5 2550.7 88% 
4879 H05 122819 657 46384.5 2902.8 89% 
4879 A06 227186 697 56313.5 3044 89% 
4879 B06 19990 770 45960.8 4889.3 88% 
4879 C06 1614 447 55486.8 3054.1 88% 
4879 D06 13051 407 53473.9 6037.5 55% 
4879 E06 59620 413 48743.4 4330.8 87% 
4879 F06 107701 416 20438.4 3080.9 86% 
4879 G06 156516 425 11793.8 2195 85% 
4879 H06 11667 474 24994.8 3080 42% 
4879 A07 159242 463 27249.2 2837.2 73% 
4879 B07 277184 454 47108.9 3519.7 38% 
4879 C07 310325 502 19687.4 2826.8 85% 
4879 D07 30663 405 25362.4 2726.1 88% 
4879 E07 158413 430 20900.3 2851.9 87% 
4879 F07 222365 435 27655.9 2725.3 89% 
4879 G07 341196 410 16723.5 2652.7 82% 
4879 H07 19970 499 34954.2 3828.5 76% 
4879 A08 3391 554 29761.7 2666 88% 
4879 B08 380802 363 17722.6 3183.3 86% 
4879 C08 645033 372 31779.4 2665.1 88% 
4879 D08 121868 423 362069.4 3041.4 89% 
4879 E08 163910 441 15044.4 2557.6 83% 
4879 F08 166259 416 76028 2648 90% 
4879 G08 168027 424 35111.6 2655.3 88% 
4879 H08 203912 410 20462.9 2503.5 87% 
4879 A09 311153 434 16277.6 5306.5 49% 
4879 B09 638432 407 1948505 1736454.
9 
52% 
4879 C09 5907 463 127741.3 92242.9 78% 
4879 D09 67436 487 52218.9 24141.1 51% 
 104 
4879 E09 96021 456 72254.3 11340 89% 
4879 F09 146557 481 26513.2 7886.1 86% 
4879 G09 308835 485 26814.4 6507.3 88% 




1H NMR of Compound 1-(4-chlorophenyl)-3-(7-nitrobenzo[c][1,2,5]oxadiazol-4-







13C NMR of Compound 1-(4-chlorophenyl)-3-(7-nitrobenzo[c][1,2,5]oxadiazol-4-




 Z-score analysis 
-Cpos = values of the positive controls 
(25 or 100 PM verapamil + 1 PM PBGT) 
-Cneg = values of the negative controls 









4860 25 78076.85 2942.1313 21907.975 605.63459 0.81 
 100 181539 452.23263 21907.975 605.63459 0.98 
4861 25 95789.025 4538.6008 19223.675 1147.0671 0.78 
 100 181866.35 17893.166 19223.675 1147.0671 0.65 
 106 
4862 25 116339.9 903.44629 22358.55 1286.3720 0.93 
 100 253081.52 21948.537 22358.55 1286.3720 0.7 
4863 25 84113.575 6702.2296 18817.85 1482.0786 0.62 
 100 169880.8 14370.498 18817.85 1482.0786 0.69 
4864 25 127424.52 6544.7259 22887.775 1480.6833 0.77 
 100 248094.57 13989.048 22887.775 1480.6833 0.79 
4865 25 126060.32 8593.8829 25499.25 490.60859 0.73 
 100 275664.67 21133.411 25499.25 490.60859 0.74 
4866 25 98025.85 5974.2999 19817.825 2339.3012 0.68 
 100 168130.77 3261.4853 19817.825 2339.3012 0.89 
4867 25 188826.5 4258.7661 28933.225 352.98937 0.91 
 100 372800.65 18294.886 28933.225 352.98937 0.84 
4868 25 158539.83 5207.8282 27416.766 780.46893 0.86 
 100 367050.73 32091.218 27416.766 780.46893 0.71 
4869 25 140178 1684.3958 26107 640.01108 0.94 
 100 288040.4 30993.961 26107 640.01108 0.64 
4870 25 346633.95 12869.774 70394.1 2876.2539 0.83 
 100 596586.55 12082.117 70394.1 2876.2539 0.91 
4871 25 79890.15 3145.8568 20502.3 1422.8076 0.77 
 100 155310.97 15007.520 20502.3 1422.8076 0.63 
4872 25 95830.85 4825.3858 18466.075 1900.9857 0.74 
 100 141608.82 7311.6649 18466.075 1900.9857 0.78 
4873 25 119502.23 19953.541 9010.2 3597.2473 0.36 
 100 267981.55 14053.393 9010.2 3597.2473 0.8 
4874 25 57642.125 942.2189 18493.5 335.36095 0.9 
 100 119336.2 7500.4482 18493.5 335.36095 0.77 
4875 25 101807.55 4334.5771 21747.7 910.27112 0.8 
 100 273818.52 12605.656 21747.7 910.27112 0.84 
4876 25 73419.075 4317.3601 27869.625 353.85905 0.69 
 100 166989.75 16723.523 27869.625 353.85905 0.63 
4877 25 172543.92 4298.0784 43931.55 1338.0930 0.87 
 100 355302.85 11942.706 43931.55 1338.0930 0.87 
4878 25 258041.25 15122.539 72781.7 1087.6716 0.74 
 100 415891.45 9683.3323 72781.7 1087.6716 0.91 
4879 25 92480.3 3265.4675 28786.8 794.39273 0.81 







List of cell lines 
Cell 
Line 
Media Growth Organism Tissue Source 




F-12 medium  

















pHaMDR-EGFP P-GP-EGFP n/a Mammalian M. 
Gottesman 
(NCI) 
 
